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EDITORIAL 
 
It is our pleasure to bring you the "Infection and 
Immunity" issue of the UWOMJ.  Today, 
infection remains an issue of great concern. While 
cancer is the leading cause of death in North 
America, infectious disease causes the greatest 
number of deaths globally. 
 
To highlight this significant topic, this 
edition of the UWOMJ incorporates a wide range 
of fascinating articles. Furthermore, exciting 
structural developments have taken place within 
the journal itself, including the addition of a brand 
new departmental section: Interdisciplinary 
Collaboration. This focus reflects the growing 
multidisciplinary nature of health care today. In 
addition, original research and case reports make 
their debut in the following pages. More so than 
ever before, our departmental editors and writers 
have collaborated in producing this impressive 
edition. 
 
We are proud that this unique edition 
brings attention to an extremely rare case of 
genitourinary tuberculosis, as well as the first 
reported case of ictal asystole secondary to an 
infection with herpes simplex virus. Our authors 
present an interesting perspective on the history 
of a well-established infection commonly known 
as fifth disease. 
 
Not only are rare and curious cases and 
medical history included, but an up-to-date 
discussion of the world's major health concerns, 
including avian influenza, tuberculosis, rabies, 
and listeriosis round out our article collection. We 
now focus on prevention on a much larger scale, 
on an international rather than on a local basis. 
For instance, the possibility of an avian influenza 
pandemic has changed our worldwide 
perspective. Major strides in combating infections 
have been made with the advent of vaccines; a 
number of our articles look at the factors 
surrounding these breakthroughs. 
 
Have you wondered what the 
environmental impact and infectious risk of your 
daily actions entail? Significant community health 
concerns are addressed in an intriguing article 
demystifying infection prevention. 
 
Furthermore, infection is a social and 
anthropological concern. Poverty, poor access to 
health care, and lack of education are just a few of 
the many determinants of health.  Such social 
factors are eloquently highlighted in a feature 
article focusing on the burden of respiratory 
infections in homeless populations. 
 
For a far more personal viewpoint, an 
intimate career interview with Dr. Marina 
Salvadori, a pediatric infectious disease specialist, 
will inspire future doctors. Her career path 
demonstrates that a genuine passion for medicine 
can translate to advocacy work, global health and 
tangible effects on health policy. 
 
Attractively binding this vast array of 
articles together, our cover art addresses the most 
pressing infectious health concern of our age – 
HIV – in both a stylistic and unique manner. The 
inside cover art is another testament to the 
genuine aesthetic talent and skill of medical 
students today. The creative geniuses of our 
artistic colleagues deliver the essence of infection 
and immunity, organized in a professional format 
designed by our new layout editor. 
 
Overall, the cutting edge pieces included 
in this issue are a tribute to the hard work and 
research talent of our contributors, authors and 
editors. As always, the collective efforts of 
University of Western Ontario medical students 
are manifested in this impressive edition of the 
UWOMJ. 
 
Special thanks go out to our managing 
editorial team for their drive and dedication in 
bringing this issue together. We would also like to 
express our appreciation for the many faculty 
reviewers who have contributed to the high 
quality of the articles published herein. Enjoy! 
- Wendy Ng and Amber Menezes 
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CLINICAL PROCEDURES 
Procedural approaches to drainage of prostatic abscesses 
 
Paul Lau (Meds 2011) and Edward Weiss (Meds 2012) 
Faculty Reviewer: Dr. Hassan Razvi, Department of Surgery, Division of Urology 
 
Prostatic abscesses are a rare complication of acute prostatitis, and an uncommon clinical entity in the 
antibiotic era. Despite their rarity, untreated abscesses still remain potentially life-threatening, and require 
formal drainage to permit resolution. The transurethral approach to drainage used in the past has more 
recently given way to percutaneous interventions aided by trans-rectal ultrasonography. Although none of 
the currently-used strategies have proven ideal for complex cases, improved imaging techniques are 
expected to further increase the efficacy of percutaneous interventions and establish them as the standard of 
practice for treating prostatic abscesses.   
 
Introduction 
 
Prostatic abscesses (PAs) are defined by the 
accumulation of purulent material in one or more 
focal areas of the prostate. With the advent of 
antibiotic therapy in the twentieth century, PA has 
become a rare clinical entity. However, it can still 
present as a complication of acute bacterial 
prostatitis, which itself is thought to be caused by 
intraprostatic urinary reflux, ascending urethral 
infection, or hematogenous spread from an 
infection elsewhere in the body. Left untreated, 
PAs can rupture and progress to sepsis, as well as 
fistulization of the bladder, urethra, and rectum.1 
Thus, the need for expeditious diagnosis and 
treatment is not to be underestimated.  
 
Symptoms of PA often mimic those of 
acute bacterial prostatitis (ABP) – fever, dysuria, 
low back and perineal discomfort, and pain upon 
palpation of the prostate. In the course of a digital 
rectal exam, the abscessed prostate is usually 
discovered to be enlarged, and sometimes 
fluctuant. The use of transrectal ultrasound or 
other imaging modalities such as computed 
tomography (CT) can provide radiological 
confirmation of the abscess even in the absence of 
prostatic fluctuation. On occasion the condition is 
suspected when the patient fails to respond to 
appropriately selected antimicrobial coverage. 
 
Before the introduction of inexpensive and 
readily-available antibiotics, prostatic abscesses 
were often seen in sexually active young men as a 
result of infection with Neisseria gonorrhoeae. 
Because of the lack of diagnostic and 
interventional strategies, many patients presented 
with systemic infection due to spontaneous 
rupture of the abscess into nearby structures and 
cavities, and mortality has been estimated to have 
been as high as 30%.2 More recently, the advent 
of antibiotic therapy has seen a marked decrease 
in the morbidity and mortality associated with 
PA, as well as concomitant changes in 
bacteriology and epidemiology. The most 
common organisms now encountered include 
Escherichia coli and Staphylococcus aureus,1,3 
and the disease is classically found in older men 
with predisposing factors such as diabetes, 
ongoing dialysis, or a history of urethral 
catheterization.1   
 
The microbiological profile of PAs has 
also shifted in the wake of the increasing 
prevalence of immunodeficiency. Patients with 
AIDS have been known to present with abscesses 
caused by Mycobacterium tuberculosis,4 and in 
other settings of immunodeficiency, such as 
immunosuppression following organ 
transplantation, organisms cultured from PAs 
have included Cryptococcus,5 Aspergillus,6 and 
Candida.7 There is also preliminary evidence 
indicating that the increasing prevalence of 
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diabetes in some regions is associated with a 
higher incidence of PA in younger men,3 which 
may reflect a significant ongoing epidemiological 
change that may be significant in the future. 
 
Variable treatment modalities exist for the 
drainage of PAs. Transurethral unroofing, 
transrectal needle aspiration or transperineal 
needle aspiration are all options currently being 
used. This article will discuss the indications and 
methods for each therapeutic approach, as well as 
their respective risks and benefits. 
 
Transurethral approach to drainage of 
prostatic abscess 
 
Previously employed by urologists as the standard 
approach, the transurethral technique to drainage 
of a PA (otherwise known as unroofing) has 
recently been replaced by percutaneous 
measures.7 However, transurethral unroofing of 
PAs is still employed for persistent abscesses that 
recur despite minimally-invasive treatment. 
 
 
The procedure is typically performed 
under general anaesthesia with the patient in the 
lithotomy position (Figure 1). An electrosurgical 
resectoscope armed with either a Colling’s knife 
or resectoscope loop is utilized to unroof the PAs 
which often are visibly apparent as a bulging 
mass.8  Transurethral approaches to drainage of 
PAs carry a risk of widespread bacteremia as well 
as all complications related to general 
anaesthesia.7 Patients may also experience 
retrograde ejaculation and rarely  urethral stricture 
and sphincter dysfunction following the 
procedure.9 Additionally, transurethral unroofing 
is ineffective in patients presenting with 
peripherally located abscesses and multiloculated 
abscesses. The location and complexity of these 
abscesses leads to incomplete drainage through 
the transurethral approach,10 a complication that 
can prove detrimental in immunocompromised 
patients. One case report has recommended the 
usage of sonographic guidance in conjunction 
with transurethral unroofing to treat complex 
abscesses; however, this has not been validated by 
further studies. 
 
Transrectal approach to drainage of prostatic 
abscess 
 
The first of two percutaneous methods to drain 
PAs, the transrectal approach utilizes a transrectal 
ultrasound (TRUS) to guide a needle through the 
rectal wall and into the PA for drainage (Figure 
2). The procedure is performed under local 
anaesthesia with the patient in the left lateral 
decubitus position.11 Lavage following drainage 
allows for antibiotics to be introduced directly 
into the post-drainage cavity.  
 
In contrast to transurethral unroofing, the 
transrectal approach can be utilized for complex 
abscesses as TRUS enables direct visualization of 
the abscess and minimal tissue manipulation 
reducing the morbidity of the procedure. This 
technique requires no general anaesthetic and is 
less painful then the transperineal approach. 
Despite the advantages of TRUS guided drainage, 
Gan et al have demonstrated that repeat 
procedures for multiloculated abscesses are 
common using this method.12 Formation of recto-
urethral fistulae and potential prostatic 
contamination by rectal bacteria may also 
complicate recovery following drainage.  
 
Figure 1. Transurethral radical prostatectomy is 
performed with a resectoscope equipped with a 
diathermy loop. The instrument is passed down the 
length of the urethra and the resection is performed 
with constant irrigation.  
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Transperineal approach to drainage of 
prostatic abscess 
 
Another percutaneous approach to drainage of 
PAs, the transperineal approach also employs the 
use of TRUS to guide a needle puncturing the 
perineum into the prostatic abscess.13 The 
procedure is painful and may require the use of 
general anaesthesia although most procedures are 
tolerable under local anaesthesia. The patient is 
placed in the lithotomy position and a needle is 
advanced from the perineum into the prostate 
(Figure 3). Following complete drainage of the 
abscess, a guidewire is placed into the cavity and 
dilatation of the puncture tract is achieved via the 
Seldinger technique. A loop catheter is then 
placed for further drainage and is left in place for 
several days.  
 
The transperineal approach is preferred 
over the transrectal approach by some clinicians 
due to the increased chances of complete drainage 
via the loop catheter. Disadvantages of the 
transperineal approach are also related to the 
inability of the TRUS to adequately allow for 
complete drainage of multiloculated abscesses. 
However, the recent utility of 3D TRUS has 
shown promising results in the management of 
multiloculated abscesses by the transperineal 
approach.  
 
Discussion 
 
In the post antibiotic era, PA is a rare 
manifestation of a urinary tract infection. 
Regardless, a failure to diagnose and promptly 
treat can cause significant morbidity. Current 
practices utilize imaging for diagnostic purposes. 
Existing data shows that the use of TRUS for the 
diagnosis of prostatic abscess is as sensitive as 
CT or magnetic resonance imaging.14 With the 
ease of use and lack of ionizing radiation, TRUS 
is the gold standard for diagnosis and 
visualization of a prostatic abscess.13 The 
diagnostic criteria include the presence of 
hypoechogeneic areas containing thick liquid in 
the transition and central zones of the prostate 
permeated with hyperechogeneic areas as well as 
enlargement or distortion of the anatomy of the 
gland. There is also a role for urinary culture for 
selection of pre-procedural antibiotics. 
 
Although all three approaches to drainage 
of PAs are still being employed, the percutaneous 
measures (transrectal and transperineal) have 
come into favour due to their less invasive nature 
and association with lower morbidity.7 Each 
procedure has been shown in literature to have 
potential for incomplete drainage although the 
recent evidence favouring 3D TRUS showed 
 
Figure 3. Transperineal needle aspiration of 
prostatic abscess. The transducer of the transrectal 
ultrasound is placed in the rectum (R), and the fine 
needle (N) has been guided ultasonographically 
into the prostate (P). 
 
 
Figure 2. A transrectal ultrasound probe with 
attached needle is used to puncture the prostate. 
NB: This image depicts a probe equipped with a 
biopsy gun. For drainage of prostatic abscesses, a 
fine needle or catheter is used, often introduced 
through an intra-probe needle canal.  
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complete drainage in all 7 patients studied.13 
Regardless of procedure, antibiotics are a key 
component in the management strategies of PAs. 
Antibiotics should be given orally or 
intravenously before any procedure to drain a 
PA.8 Once drainage is complete, culture and 
sensitivity testing allows for a more targeted 
approach towards eradication of the infection. 
 
Conclusion 
 
With the incidence of prostatic abscess at a 
historic low, it is likely that many clinicians may 
go their entire careers without encountering what 
was once a fairly common presentation. However, 
the possibility of severe sequelae pursuant to an 
untreated PA and the suggestion that its incidence 
may rise in the future represent a strong impetus 
for becoming acquainted with the diagnostic and 
interventional strategies required to treat PA. 
Percutaneous transrectal or transperineal needle 
aspiration with ultrasonographic guidance have 
shown to be effective and minimally invasive 
treatment modalities, and future refinement of 
current ultrasound technology promises to extend 
successful treatment to more complex and 
resistant abscesses. 
 
Acknowledgements 
 
Figure 3 reprinted with permission from 
Weinberger M, et al. (1988), copyrighted 
University of Chicago. 
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DIAGNOSTIC REVIEW 
Avian influenza: an emerging infectious disease with pandemic 
potential 
 
Jason Essue (Meds 2011) and Rachel Bevan (Meds 2012) 
Faculty Reviewer: Dr. John McCormick 
 
There are numerous examples of infectious diseases that have wreaked havoc on the human population.  
Analysis of previous outbreaks has provided insight into the various ways that infectious diseases can be 
transmitted both between members of different species and among members of the same species.  
Furthermore, a thorough understanding of past outbreaks enables public health agencies to develop an 
informed approach to predict when new emerging or re-emerging infectious diseases will surface.  
Anticipating an infectious disease outbreak is essential to preparing an effective response strategy. The 
transfer of disease between species is of particular concern as a reservoir of emerging infectious diseases 
(EIDs) since approximately 75 percent of EIDs are estimated to have zoonotic origin. Bird-flu, or influenza 
strain H5N1, is an emerging disease of avian origin that is expected to cause the next influenza pandemic 
and has already begun to surface in humans from a wide geographic area.  Frontline clinicians need to be 
aware of the signs and symptoms of H5N1 infection.  Successful control of an H5N1 outbreak relies upon 
accurate identification by clinicians, reporting of an outbreak to public health authorities, and 
implementation of infection control procedures in a timely manner.   The continued development of new 
technological advances that surpass traditional national boundaries, in order to track and report infectious 
diseases, is integral for rapid and efficient communication among public health agencies. 
 
Introduction  
 
Throughout history, numerous infectious diseases 
have had a large impact upon human health, 
through well-known epidemics such as the 
bubonic plague, (which most recently broke out in 
China in 1855 and is still ongoing) influenza (in 
1918 and again in the 1950s), the current HIV 
pandemic, and also through the re-emergence of 
infectious agents such as Methicillin Resistant 
Staphylococcus aureus (MRSA).2,3   Infectious 
diseases are estimated by the World Health 
Organization (WHO) to have caused 
approximately twenty-five percent of world-wide 
deaths in 2002 (15 million people, excluding 
complications due to infection as a cause of 
death).1  Furthermore, the impact is greatest upon 
the disadvantaged and children.1 Influenza 
epidemics in particular have demonstrated the 
ease with which infectious diseases can spread 
throughout the global population,3 and remain a 
concern as a re-emerging infectious agent.4 
 
Emerging Infectious Diseases (EIDs) 
EIDs are infectious diseases that have either an 
increasing range or incidence.  EIDs are 
discovered for various reasons: a previously 
unknown disease variant is discovered (e.g. 
Helicobacter pylori as a cause for ulcers); a new 
agent is created (e.g. Avian Flu is currently an 
emerging infectious disease); and the re-
emergence of a disease after an initial period of 
decline (e.g. plague caused by Yersinia pestis is 
known to have caused at least 3 known pandemics 
which occurred hundreds of years apart).2,3  
Factors that precipitate or enhance the spread of 
EIDs can be categorized as either those that aid in 
the introduction into the host population of the 
infectious agent, or those that allow the infectious 
agent to become established and spread 
throughout the population (Table 1).  
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There are two categories of factors that 
promote EIDs: those that promote EID 
introduction, and those that promote EID spread. 
Note that the activities are taken directly from 
Institute of Medicine’s factors for EID.2,3 
 
One analysis of 335 EID events from 1940 
to 2004 demonstrated that there has been a 
significant increase in EIDs over time, even when 
accounting for reporting bias.5  Based upon this 
analysis, the majority of EIDs diseases came from 
zoonotic events (60.3%), and were caused by 
either Rickettsia (gram negative bacteria) and 
other bacteria (54.3%).5  Globally, the distribution 
is non-random.  Indeed, EIDs are most likely to 
occur in the lower latitudes, where the fewest 
global resources are focused, and reporting is 
least common.5  Furthermore, despite the 
development of numerous antibiotics and 
vaccines, diseases caused by viruses, protozoa, 
helminths and fungi are still difficult to treat and 
eradicate.2    
 
Zoonotic origins of EIDs 
 
In general, one of the greatest causes for concern 
of newly EIDs is the reservoir found in animals.3,6  
Such diseases can transfer to humans either 
directly, or through a vector (such as arthropods), 
and have the potential to cause epidemics.  The 
potential for epidemics is especially a cause for 
concern if the disease develops the ability to 
easily transmit between individuals within a 
population.3 Diseases such as HIV and H5N1 
(bird-flu) are examples of diseases of zoonotic 
origins.  HIV, which is one of the most prominent 
examples of an infectious disease of zoonotic 
origins, is thought to have transferred from 
simians in Africa through the consumption of 
bush meat.4    
 
Bird-flu, or influenza strain H5N1, is a 
newly emerging disease of particular public 
health concern.3  Influenza is a rapidly mutating 
disease with two key surface proteins 
(hemagglutinin and neuraminidase) that have a 
large effect upon the successful spread and 
virulence of the disease.  Hemagglutinin is an 
influenza surface protein that helps the virus to 
bind to cell surface receptors.  Key mutations in 
hemagglutinin allow the influenza virus to bind 
host cells when host immunity has developed 
against other hemagglutinin antigens.4 There are 
at least 16 known hemagglutinin subtypes.  
Neuraminidase is another influenza surface 
enzyme that confers virulence to influenza.4 It is a 
glycosidic hydrolase enzyme with nine subtypes, 
many of which are present only in birds. 4   H5N1 
represents an influenza strain that has not 
previously infected humans, and contains a 
combination of the H5 hemagglutinin and N1 
neuraminidase subtypes.3 Currently, H5N1 is 
highly virulent in chickens, and has begun to 
infect migratory birds. 3 It also has the ability to 
jump to humans and other mammals (including 
pigs), where it causes a high death toll. 3 
 
 
 
Table 1: Factors that promote the introduction and spread of emerging infectious diseases.   
 Activity Example
Factors that promote 
introduction of EIDs 
Economic Development 
and Land Use 
Exposure to living conditions that allows for zoonotic 
transfer (e.g. H5N1)
Microbial Adaptation Methicillin Resistant S. aureus (MRSA) 
Factors that promote spread 
of EIDs 
International travel & 
commerce 
Severe Acute Respiratory Syndrome (SARS)
Change/breakdown of 
public health measures
Measles and Rubella outbreaks 
Technology & Industry Food poisoning outbreaks
Human 
demographics/behaviour
Human Immunodeficiency Virus (HIV) 
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H5N1: the next pandemic? 
 
Although H5N1 is largely expected to cause the 
next influenza pandemic, the following conditions 
must first be met for this to occur: 1) a new 
influenza virus subtype must emerge, 2) it must 
be capable of infecting humans and causing 
serious illness, and 3) it must spread easily from 
human to human.7,8  H5N1 is of particular 
concern because it has already fulfilled the first 
two criteria and more recent reports from the 
World Health Organization (WHO) suggest that 
partial human-to-human transmission of H5N1 
may  have occurred in isolated cases in Thailand, 
Indonesia, and Vietnam.7,8,9,10  However, at 
present, human-to-human transmission has 
occurred sporadically and with very low 
efficiency and therefore does not meet the third 
criteria.7,8,11  Nonetheless, influenza-like viruses 
are highly mutagenic11 and may become freely 
transmissible among humans at some point in the 
future, which means that the threat of an avian 
influenza pandemic remains very real.   
 
Based upon past influenza epidemic 
outcomes, the United States Congressional 
Budget Office (CBO) has projected that a 
potential influenza pandemic could involve 200 
million people infected, 90 million clinically ill, 
and 2 million dead.  This would yield a case-
fatality ratio of 2.5%.  Furthermore, the economic 
cost could reach $675 billion.12 As of September 
2008, the WHO reported that H5N1 has already 
infected 387 humans and killed 245 patients 
worldwide, with a case-fatality rate of 63%.12  
Therefore, the CBO’s projection likely 
underestimates the actual impact of an H5N1 
pandemic given that the case-fatality ratio of 
H5N1 reported by the WHO is 25 times greater 
than the estimate put forth by the CBO (63% vs. 
2.5%).   
 
Signs of Symptoms of H5N1 Infection 
Frontline clinicians need to be aware of the signs 
and symptoms of H5N1 infection because 
identifying the illness, reporting it to public health 
authorities, and implementing infection control 
procedures in a timely manner offers the best 
chance of controlling the spread of infection.  
Symptoms include typical influenza-like 
symptoms: fever greater than 38°C (100%), 
cough and sore throat (67%), myalgias (30%), 
pneumonia (58%), and diarrhea and vomiting 
(50%).7  Symptom onset occurs within 2-14 days 
of exposure.11,14  Complications include acute 
respiratory distress syndrome (ARDS), 
pulmonary hemorrhage, myocarditis, pericarditis, 
encephalitis, multi-organ failure with renal 
dysfunction, and sepsis.7  Common radiographic 
findings include diffuse, multi-focal or patchy 
infiltrates and segmental or lobar consolidation 
with air bronchograms.7  The majority of the 
deaths have been attributed to respiratory failure.7  
 
Diagnosis and Treatment of H5N1 
Diagnosing H5N1 infection poses a challenge 
because there are no pathognomonic signs and 
symptoms making it difficult to distinguish from 
other causes of influenza-like illness, severe 
community-acquired pneumonia, or ARDS.7,11,14  
The only findings that would raise suspicion of 
avian influenza (H5N1) is a history of presence in 
an endemic area and/or contact with 
poultry.7,11,14,15  Therefore, obtaining a detailed 
history including travel and animal exposure is 
crucial.  When H5N1 infection is suspected, the 
preferred test to confirm the diagnosis is real-time 
reverse transcriptase polymerase chain reaction 
(qRT-PCR) on a nasopharyngeal swab.7,11,16  
 
Current opinion of the WHO states that 
patients presenting with the symptoms and 
historical features that are strongly suggestive of 
H5N1 infection should promptly be started on a 
course of Oseltamivir, pending the diagnostic 
results of PCR testing. 17 Oseltamivir is an 
antiviral agent that inhibits neuraminidase, which 
has been shown to reduce H5N1 infection-
associated mortality in observational studies when 
it is administered in a timely manner.17   
 
Mandatory Reporting of H5N1 
Laboratory confirmation of a human case of 
H5N1 by qRT-PCR should trigger an immediate 
notification of local, sub-national, and national 
public health and agricultural authorities.  
However, the collection, shipment, and testing of 
specimens can often take several days or longer.  
Therefore, it is often necessary to notify the 
appropriate public health officials and initiate an 
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investigation before laboratory test results are 
available for persons suspected of having H5N1 
infection.18,19  National health authorities must 
then notify the WHO and readily share 
information and biological specimens.19,20   
 
New methods of surveillance and reporting 
EIDs 
 
Although this reporting structure provides a solid 
basis in order to approach outbreaks in a globally 
concerted manner, the hierarchical nature of the 
system could cause unwanted delays in 
communication from the local governmental level 
to the WHO.  Furthermore, some parties may be 
less willing to report potential new H5N1 
infections for fear of local or national economic 
repercussions, leading to further delay.20 For these 
reasons, new structures of communication are 
being created by public health scientists to share 
information more rapidly.  ProMED-mail is an e-
mail based group dedicated to infectious diseases 
with a membership exceeding 30,000, giving the 
group global reach and influence.21 ProMED is 
known to report outbreaks before local 
authorities.  During the 2003 SARS epidemic, 
that spread from the Guangzhou province in 
China to nearly 37 countries22, the first public 
report of the epidemic was posted on ProMED 
more than a month before the Chinese 
government’s official announcement.21  
ProMED’s membership is volunteer-based and 
not affiliated with a governmental organization.  
Therefore, they have greater freedom to report 
what they observe than official organizations, 
which may have political constraints on what they 
can publicly report.  This on-the-ground reporting 
is thought to push governments to disclose more 
information than they might normally.21   
 
HealthMap (http://www.healthmap.org/) 
is a newer surveillance system that continuously 
monitors the internet, aggregating real-time 
information on infectious disease outbreaks from 
news media sources, blogs, and discussion 
groups.23 HealthMap illustrates the distribution of 
reported infectious diseases by superimposing 
these incidents on a map of the world.   The WHO 
is one of its top users.23 This is significant 
because it allows WHO to learn of emerging 
infectious disease without having to exclusively 
rely on local public health agencies.                
 
Conclusion 
 
In summary, there are a variety of 
infectious agents capable of causing disease in 
humans.  H5N1, a virus of avian origin capable of 
crossing the species boundary to infect humans, 
has the potential to cause the next influenza 
pandemic and is thus of particular concern.   In 
order to adequately respond to the next outbreak, 
frontline clinicians need to be eternally vigilant at 
the community level.  Furthermore, clinicians 
must be aware of the need to act in a concerted 
manner with other nations at the global level.  
New technological advances should be fully 
exploited to facilitate such globally coordinated 
responses.  The next pandemic will not observe 
national boundaries, and our approach to the 
control of EIDs should reflect an awareness of 
this.  The global community cannot afford to let 
state boundaries prevent a necessary response to 
the emerging pandemic threat posed by avian 
influenza, or any other emerging pandemic threat. 
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Despite the declaration of tuberculosis (TB) as a global health emergency by the World Health 
Organization in 1994, many in North America were unaware of the rapidly increasing health burden of TB 
until the highly-publicized Andrew Speaker incident.  Speaker, an American lawyer, knowingly left the 
United States while infected with extremely drug-resistant TB and prompted an international health scare 
which led to the first federal quarantine order since 1963.  This incident highlights the growing concern of 
emerging drug-resistant strains of tuberculosis, regarding which the WHO issued a global alert in 1996.  It 
also raises many issues meriting ethical examination, including public health measures to control TB, 
individual obligation to avoid infecting others, and the role of the physician in infectious disease control. 
 
The global health burden of tuberculosis 
 
Historically a leading cause of human mortality, 
tuberculosis was thought to be on its way to being 
eradicated in North America as early as the 
1950s.  This decline was interrupted by a highly 
publicized resurgence in New York City during 
the 1980s and 1990s, primarily among homeless 
and HIV positive individuals.  The epidemic was 
eventually brought under control in the 1990s 
following enormous health care expenditure and 
coercive public health measures, including 
mandatory directly observed therapy (DOT) and 
detention of patients who were noncompliant with 
their prescribed treatment regimen.4  However, 
TB has remained a significant issue all along in 
developing nations; with one-third of the global 
population infected with a latent form, TB is 
currently the second leading infectious cause of 
mortality worldwide.5 
 
Prior to the Speaker incident, awareness of 
the increasing global health burden of TB had 
been largely overshadowed in Western society by 
media focus on the HIV/AIDS epidemic.  The 
episode also highlighted the threat of emerging 
drug-resistant strains of tuberculosis.  
Approximately 20 percent of worldwide TB cases 
are identified as multi drug-resistant (MDR-TB), 
and 10 percent of these are extremely drug-
resistant (XDR-TB).6 MDR-TB is defined as TB 
resistant to at least two of the four first-line 
medications, namely isoniazid and rifampicin.  
XDR-TB refers to MDR-TB, in addition to 
resistance to fluoroquinolones and any one of the 
second-line anti-TB drugs.6 
 
The Speaker incident 
 
Despite acknowledgement from the US Centers 
for Disease Control (CDC) and the WHO of the 
emergence and spread of extremely drug-resistant 
TB (XDR-TB),7 the issue did not receive 
extensive attention until Andrew Speaker became 
a household name in May 2007.  Speaker tested 
positive for tuberculosis in January 2007, 
following a pulmonary abnormality detected on 
chest x-ray and CT scan, and a subsequent 
diagnostic bronchoscopy, for which he was 
prescribed a standard regimen of first-line 
medications.2 He underwent susceptibility testing 
at the Fulton County TB Clinic in Georgia 
following the disclosure that he planned to travel 
overseas for his honeymoon in May 2007.  This 
susceptibility, or sensitivity, testing was done to 
determine the likelihood that his drug treatment 
regimen would be effective in eliminating or 
inhibiting the growth of the infection.  The results 
indicated that Speaker was infected with multi 
drug-resistant tuberculosis. 
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Despite being advised by his primary care 
physician and the Fulton County Health 
Department that he should not embark on his 
planned international travel, Speaker flew to 
Europe without informing any public health 
official.  The discovery through further sample 
analysis that he had XDR-TB prompted a nation-
wide border alert, and the Center for Disease 
Control located Speaker in Rome and instructed 
him not to travel on a commercial aircraft because 
of the significant threat he posed to other 
passengers.  Despite this warning, Speaker flew to 
the Czech Republic and then to Canada, having 
correctly assumed that there was an order 
preventing him from boarding any US-bound 
flight.  He reentered the US by automobile and 
was promptly discovered by the CDC and served 
the first provisional federal quarantine order since 
1963.2 
 
Public health versus individual liberty  
 
One of the main ethical challenges highlighted by 
the Speaker case is how to balance public health 
concerns, which encompass the utilitarian aim to 
promote the greater good, against the libertarian 
aim of protecting individual rights and liberties.  
Most would agree that neither public nor 
individual interest should always be given 
absolute priority over the other.  The challenge, 
therefore, lies in striking an ethically acceptable 
balance between these two interests. Speaker’s 
actions raise questions concerning the ethical 
obligation of individuals to avoid infecting others, 
which follows from the accepted ‘duty to do no 
harm.’8  However, there must be limits to these 
duties, as it would be excessive and virtually 
impossible for all potentially infected individuals 
to take all possible precautions to avoid infecting 
others.  There is no disputing that Speaker 
behaved in an ethically inappropriate manner in 
ignoring the health authorities’ traveling advisory.  
One must also realize, however, that an ethical 
obligation to avoid infecting others must involve 
full understanding of the risk of infection.  One of 
the points of controversy in this case involves 
Speaker’s allegations that he was initially simply 
cautioned against, and not explicitly prohibited 
from, traveling.8 Regardless of the truth of this 
claim, we may learn from it that we, as health 
care providers, can strengthen this ethical 
obligation to avoid infecting others by making 
certain the patient has full knowledge and 
understanding of the risks involved in 
undertaking a particular action.  Relevant to this 
case, these include knowledge of the transmission 
of tuberculosis through airborne spread, the 
nature of drug-resistant TB, and the dangers of air 
travel and the risks posed to others.    
 
It might also be possible that Speaker was 
not adequately reassured that he would receive 
acceptable care in Italy, or be returned to the US 
in a timely manner for treatment.  While he might 
have been aware of the risk he posed to his fellow 
travelers in returning to Canada, his sense of 
ethical obligation might have been distorted 
through a lens of fear following a frightening 
diagnosis of extremely drug-resistant TB.  
Although it is also entirely possible that his 
actions were driven by selfishness and self-
interest rather than fear, the health authorities 
could have endeavored to alleviate this fear by 
assuring him of the quality of TB-related care in 
Italy and providing him with a plan and timeline 
for returning him to the US. 
 
Another ethical challenge regarding TB 
control, along with other infectious diseases, 
follows from the concept that an individual is 
both a victim of disease and a vector by which the 
disease may be transmitted to the greater 
population.9 How may we determine to what 
extent isolation measures, namely the coercive 
restriction of movement, are justified for the 
purpose of TB prevention, and who should be 
confined?  Factors to consider in making these 
decisions include whether or not the patient is 
infectious and the risk the free movement of the 
patient poses to the general population.  There is 
an obvious difference between confining someone 
with active illness and refuses to take their 
medication from someone with latent illness or a 
very low risk of contagion.  One of the ethical 
failings in the control of the New York City TB 
epidemic involved the confinement of 
noninfectious patients who, although labeled as 
‘recalcitrant’ for failing to take their medications 
properly and to report for scheduled medical 
appointments, posed no immediate infectious 
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danger to others.4  One of the interesting aspects 
of the Speaker case is that, although he was 
infected with an XDR-TB strain, his level of 
contagion was actually quite low, yet he was still 
placed and kept under federal quarantine for 
several months.2 It would not be unreasonable to 
infer that the isolation measures were therefore 
influenced by his noncompliant behavior and the 
threatening nature of his diagnosis, as opposed to 
strictly his level of infectious risk.  As physicians, 
we should advocate for appropriate diagnostic 
tests to assess the patient’s level of infectivity and 
for evidenced-based isolation measures that are 
appropriate to the risk posed by the patient. 
  
Fear-Driven Public Health Measures 
 
Smith, Battin et al. discuss the ethics of public 
health decision-making regarding infectious 
diseases in context of their overwhelming ability 
to provoke fear and panic in populations.9 They 
argue that this fear can lead to emotionally-driven 
decision making that challenges basic medical 
ethics principles such as autonomy and social 
justice.  In certain instances, the results of these 
decisions may be positive.  For example, during 
the New York TB outbreak, the decision to 
institute mandatory directly observed therapy was 
motivated by the recognition of drug-resistant 
strains of the disease that were more difficult to 
eradicate, and this eventually helped to stem the 
outbreak.  However, in other instances, fear-
driven public health procedures may come into 
conflict with bioethical principles or even basic 
human rights.  South Africa’s current policy 
involves enforced quarantine of patients with 
drug-resistant TB in prison-like hospitals with 
high fences patrolled by guards to prevent 
escape.10 Although the country is battling the 
highest global TB prevalence with a concurrent 
HIV/AIDS epidemic, some patients are required 
to spend several years in hospital, long past the 
point of infectiousness.  Several recent studies 
have ascertained that these hospitals can, in fact, 
serve as breeding grounds for drug-resistant TB, 
such that patients with MDR-TB are contracting 
XDR-TB strains at an alarming rate.11 Thus, not 
only is this enforced quarantine a challenge to 
patient autonomy and human rights, but it is 
posing additional risk to the patients and is a huge 
financial burden on an already weak health care 
infrastructure. 
 
The enormity of the media attention the 
Speaker case received, as well as the issue of the 
first federal quarantine in over 40 years, 
highlights the panic and fear that the emergence 
of drug-resistant tuberculosis has engendered in 
Western society.  Given that his actual contagion 
was low, one must wonder whether the nature of 
his diagnosis with XDR-TB and the fearful 
response provoked by his actions influenced the 
health authorities’ decision to take extended 
isolation measures.  This highlights our role as 
physicians in an era of mass media coverage to 
put infectious diseases and epidemics into context 
for the general public, and to assuage community 
hysteria when it is disproportionate.  We have an 
ethical obligation to help our patients understand 
the severity of a situation, such as the danger 
posed by travel with infectious disease, but must 
also help public health authorities to minimize 
fear-driven decision making that is non-evidence-
based or ethically suspect.  
 
Social Justice in Tuberculosis Control 
 
Another interesting aspect of the Speaker incident 
involves the fact that the case of one infected 
individual traveling through the developed world 
could generate so much media attention and bring 
the issue of drug-resistant TB to the global stage, 
when it has been a serious problem all along in 
developing nations.  Speaker does not resemble 
the typical TB patient in that he is a wealthy, 
white, educated male from a developed country.  
Infectious diseases affect primarily the poor and 
developing world due to lack of sanitation and 
weak healthcare infrastructure, among other 
factors.  When making public health decisions 
that may pose ethical challenges and infringe 
upon individual rights and freedoms, it is 
important to consider the nature of the population 
these decisions will affect.  As developing nations 
are oppressed by virtue of their economic 
position, and will shoulder the burden of public 
health measures for the control of tuberculosis, it 
is important to give consideration to individual 
rights where possible, as the “blame, stigma, and 
ostracism associated with isolation and quarantine 
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are especially real for diseases linked to the 
poor… or the disenfranchised.”2 
 
Conclusions 
 
Though by no means exhaustive, the ethical 
issues highlighted with respect to the Speaker 
incident illustrate the need for ethical reflection in 
developing public health policies for tuberculosis 
control.  Drug-resistant tuberculosis, which has 
now become a global threat, is largely propagated 
in poor countries where poverty and a weak 
health care infrastructure often preclude finishing 
a full course of TB treatment.  Improved health 
care provision in endemic areas would therefore 
reduce the frequency by which we would have to 
make public health decisions that challenge 
individual rights and freedoms.  The role of the 
physician must involve providing the patient and 
the public with appropriate and adequate 
information in order to strengthen individual 
obligation to do no harm, as well as to prevent 
community panic and emotionally-driven decision 
making which can lead to public health policies 
that infringe upon the rights of the individual. 
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In the mid-20th century, industrialized countries underwent the ‘epidemiological transition’ whereby the 
leading cause of death evolved from infectious and parasitic to chronic and degenerative diseases.11 This 
transition, however, has not yet occurred in many developing countries.11 In 2002, infectious and parasitic 
diseases caused the greatest burden in disability-adjusted-life years (DALYs) to human beings worldwide.16 
Although the threat of infectious and parasitic diseases in developed countries such as Canada has 
decreased since the middle of the last century, protecting ourselves against such diseases should remain a 
priority since we reside in a global community. We take this opportunity to explore three “urban legends” 
of day-to-day infection prevention and determine whether there is truth to these myths. 
 
Hand towels vs. air dryers 
The Myth 
The Centres for Disease Control and 
Prevention (CDC) has a list of recommendations 
regarding hand-washing, which includes drying 
hands using a paper towel or air dryer.23 This step 
in the procedure has sparked considerable debate 
in the infectious disease realm.  Are paper towels 
or air dryers more effective?  Proponents of 
towels argue that you may as well not wash your 
hands if you insist on using air dryers as they just 
blow the germs back on.  Proponents of air dryers 
lament the environmental impact of towels.  
Unfortunately, the literature is similarly divided 
on the issue. 
 
The Evidence 
Early studies on this topic were strongly in 
favour of hand towels.  In 1984, one of the first 
comparisons of the two drying methods found 
that paper towels could reduce bacteria on hands 
by 55% while air dryers achieved a dismal 9% 
reduction.4 Subsequent studies found towels to be 
safer and more hygienic than air dryers,6,7 while 
one study even found that not only were air dryers 
less effective, but they actually increased the 
number of microorganisms left on hands.4   
 
 Uncertainty began to mount in 1991 when 
a study in the American Journal of Infection 
Control reported that air dryers were more 
effective in reducing the numbers of Escherichia 
coli and rotavirus from hands.3 The argument was 
levelled when a randomized control trial 
conducted in 2000 failed to find a significant 
difference in bacterial numbers when the use of 
rotary dispenser towels, stacked paper towels, air 
dryers, and spontaneous evaporation were 
compared.2 It is interesting to note that in a 
separate study, it was found that hands that were 
held stationary under the dryer retained fewer 
bacteria than rubbed hands.4  This difference was 
explained by the fact that rubbing allows bacteria 
to migrate from the hair follicle to the skin 
surface, thus the finding may simply be a 
measurement bias.  Nonetheless, they concluded 
that stationary hands under an air dryer was the 
best method, followed by a tie between paper 
towels and rubbed hands.4 
 
When investigations were broadened from 
microbes remaining on hands to microorganisms 
in the washroom environment, the equivocality 
remained.4 Taylor et al concluded that in 
bathrooms equipped with paper towels, the germs 
were transferred from the hands to the towels, 
which were then disposed of in open receptacles 
where they acted as reservoirs of bacteria.  In 
contrast, while the air dryers killed a sizable 
proportion of microorganisms by virtue of the 
heater, the splattering of water droplets onto the 
wall behind the dryer made this one area of the 
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bathroom to avoid.  This dispels the myth put 
forth by towel proponents: air dryers do not just 
concentrate microorganisms from the air onto the 
users’ hands, as evidenced by the fact that dryer 
outflow contained significantly fewer organisms 
than inflow.4   
 
The Verdict 
Despite the controversy, all studies were 
in agreement about the importance of hand 
washing.  Proponents of towels can argue using 
evidence from early literature, the finding that 
paper towels were more effective in removing 
bacteria from the fingertips in particular1 and the 
CDC recommendation that one use a paper towel 
to turn off the tap.23  They may also argue that air 
dryers are not recommended in critical care 
environments due to the possibility of air 
dispersal of bacteria-laden droplets.8  Air dryer 
enthusiasts can cite findings from more recent 
studies, environmental considerations, and the 
capacity to remove bacteria from the air.  
However, there is no clear victor in this debate.  
The important takeaway points are to wash your 
hands well; if you choose a towel, dispose of it in 
a closed receptacle; if you choose an air dryer, try 
to use an automatic model and don’t rub your 
hands. 
 
Antiseptic hand sanitizers vs. soap and water 
The Myth 
Since Semmelweis’ groundbreaking 
observations in 1847 that proper hand sanitization 
measures can reduce infection rates, health 
professionals have been provided with procedures 
and guidelines aimed to perfect the hand washing 
process.4  These guidelines are applicable both in 
the hospital and the community since  hands serve 
as the main vector for micro-organism transfer.6  
However, poor compliance with hand hygiene has 
been attributed to a variety of factors including 
lack of time and skin irritation.22 Antiseptic 
sprays and rubs have been introduced as a means 
to confront these problems, however the question 
remains: do the new methods work as well as 
traditional hand-washing? 
 
The Evidence 
Hand-washing involves the use of plain 
soap and water to clean hands, whereas antiseptic 
hand-washing employs a soap containing an 
antiseptic agent, which differs from an antiseptic 
hand rub in that the latter does not require water.25 
 
 Plain (non-antimicrobial) soaps are an 
effective means by which to reduce both the 
transient bacteria colonizing the superficial layers 
of skin and the transmission of these pathogens.24 
These soaps do not, however, remove the resident 
flora found in the deeper layers of skin.24 Prior to 
surgery, antiseptic hand-washing scrubs are 
typically employed, as these are more effective in 
eliminating bacteria.25 Some centres have 
introduced pre-surgical rubs, further highlighting 
the inconclusive nature of the literature. 
 
 With respect to hand rubs, chlorhexidine- 
and alcohol-based products are two common 
varieties. Chorhexidine rubs are efficient in 
eliminating gram positive bacteria, but are not as 
effective for gram negative bacteria and 
nonenveloped viruses.25 Further, certain bacteria 
have been demonstrated, in vitro, to adapt and 
develop resistance against chlorhexidine, leading 
to resistance to other anti-infective agents.24 The 
epidemiological implications of these findings in 
humans are not yet fully understood and require 
further study.25   
 
Conversely, while alcohol-based rubs 
have minimal residual activity25 and do not 
effectively eliminate bacterial spores, protozoan 
oocytes or certain nonenveloped viruses25, there 
have been no reported cases of acquired 
resistance to these rubs. Furthermore, alcohol 
does prevent the transfer of certain nosocomial 
pathogens and effectively reduces bacterial load 
on hands.25  
 
The Verdict 
Conflicting evidence exists in the 
literature as to the effectiveness of the various 
antiseptic agents used for handwashing, which is 
due in part to the fact that not all studies assess 
effectiveness in the same manner.26,27 However, a 
review by the CDC found agreement among 
studies that alcohol-based handwashes and rubs 
are more effective in eliminating bacteria on 
hands than plain soap, and often more so than 
antimicrobial soaps.25 Their effectiveness, 
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however, is dependent on a variety of factors 
including the type, concentration, and volume of 
alcohol used.  
 
Plastic water bottles 
The Myth 
Plastic water bottles have recently been 
the subject of much debate in the media.  The 
litany of offences attributed to the vessels include: 
acting as a reservoir for germs, leaching toxic 
chemicals, and posing unnecessary stresses on the 
environment.10,13,18  Waterloo has banned the sale 
of plastic water bottles in schools and Toronto 
appears poised to follow suit in 2009.18  Despite 
these controversies, bottled water continues to be 
a $35 billion industry, with 1.7 billion gallons 
consumed last year (nearly 3000 Olympic 
swimming pools’ worth).17  This exorbitant 
consumption also means that 150 million water 
bottles are disposed of each day.9  A seemingly 
probable solution would be to reuse the water 
bottle, but the literature suggests that this 
environmentally friendly solution could wreak 
havoc on our health. 
 
The Evidence 
Researchers in Calgary selected an 
elementary school as their source of water bottles 
for analysis in 2002.10 They found that total 
coliforms exceeded Canadian Drinking Water 
Quality guidelines in 13.3% of water bottles 
examined; 8.9% contained fecal coliforms, and 
64.4% contained heterotrophic bacteria.  While 
heterotrophic bacteria are not necessarily 
pathogenic, they are a marker of overall water 
quality.20  Some of the students had left water 
bottles for months without a proper cleaning- 
significantly longer than the eight  hours that the 
literature suggests it takes for bacterial 
regrowth.10 When combined with the finding of 
no significant microbial content of water sources 
(taps and fountains), the researchers determined 
that the germs were coming from the bottles.  
 
 Several studies have suggested that plastic 
water bottles provide a better breeding ground for 
bacteria than glass or metal.12 Plastic bottles tend 
to contain fast-growing bacteria (pseudomonads, 
Flexibacter, and Acinetobacter), numbering in the 
realm of 105 cfu/mL after one week of growth.12  
In contrast, glass bottles contained slow-growing 
bacteria (mainly Acinetobacter) and were an order 
of magnitude less in quantity.  Not only is the 
type of material important, but the quality.  Jones 
et al. isolated mainly coccoid bacterial cells from 
the caps of plastic water bottles, while rod-shaped 
cells were found adherent to the walls of PET 
bottles.15  Rougher surfaces were associated with 
a significant increase in bacterial numbers. 
 
 The issue in the Calgary study was not the 
use of plastic water bottles, but the subsequent 
reuse.  Both nonpartisan researchers and the 
Canadian Bottled Water Association have 
established that bottled water does not contain 
E.coli, coliforms, Giardia, or cryptosporidium at 
the time of bottling.13,19  The real problem lies in 
the fact that water at room temperature is an ideal 
environment for microbial growth.  A simple 
solution would seem to be meticulous washing of 
the water bottles.  However, this solution was 
discredited by a 2001 presentation by a University 
of Idaho student who found that realistic reuse 
simulation (sunlight, heat, physical degradation) 
released a number of chemicals from the plastic 
water bottles into the drinking water.13 The longer 
water bottles were reused, the more organic 
chemicals were leached from the material. 
 
 The environment vs. health debate has 
thus seemingly reached an impasse- reusing water 
bottles is good for the environment but sets up a 
bacterial breeding environment, necessitating 
vigorous cleansing, which in turn liberates toxic 
chemicals.  One appears to have the choice 
between infection, intoxication, or pollution.   
 
The Verdict 
The evidence is fairly clear that water 
bottles pose a threat both to human health and to 
the environment.  However, a little common sense 
may go a long way in settling the clash of values.  
Soft-plastic water bottles such as those sold in 
vending machines should not be reused as their 
ability to stand up to the vigorous washing needed 
in order to prevent colonization has not been 
established.  Hard-plastic, glass and metal water 
bottles may be more well suited to the challenge 
of multiple uses and their use is condoned by the 
Minister of Health Canada.21  Water bottles 
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should be thoroughly washed in hot soapy water 
after each day of use. 
 
It is very difficult to come to generalized 
conclusions as to the safety of water from 
municipal taps and from rural wells as compared 
to bottled water. The importance of the presence 
of trace amounts of chemicals in tap water as 
compared to bottled water is not known.  
Moreover, the entire picture needs to be examined 
– the energy required in making, bottling, and 
distributing bottled water is immense and this 
may impact not only the individual consumers, 
but also the health of human populations. The 
safety of the individual must be weighed with the 
potential harm the use of water bottles has on the 
environment.  For water bottles, whether single 
use or washed multi-use, the evidence is 
inconclusive.  
 
 Three common societal beliefs have been 
discussed that may impact our lives as individuals 
or as a population.  This paper attempted to use an 
evidence-based approach to make 
recommendations.  It is also important to review 
the evidence as a whole to consider the threats to 
the individual, to the people in the immediate 
environment, and to the broader global 
community.  Given the human health importance 
of hand-drying techniques, hand sterilizers and 
water bottles, it is suggested that the apparent 
simplicity of these issues not deter future 
research.  
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The purpose of this paper is to provide a detailed overview of how and when the associations between 
erythema infectiosum, fifth disease, and parvovirus B19 were established. Attention will be paid to the 
discovery of a “milder form of rubella” in 1889; the naming of erythema infectiosum in 1899; the 
emergence of the name “fifth disease” in 1905; the discovery of parvovirus B19 in 1975; and the eventual 
linking of erythema infectiosum and parvovirus B19 between 1983 and 1985. 
 
Introduction 
 
Erythema infectiosum is a common rash-like 
illness that often occurs during childhood and is 
caused by parvovirus B19.1 It is also known as 
“fifth disease” and “slapped cheek disease,” the 
latter of which refers to the condition’s 
characteristic, red rash. While most medical 
students will cover these details at some point in 
their medical training, they may never know how 
the connections between erythema infectiosum, 
fifth disease, and parvovirus B19 were 
established, and where these terms come from. 
 
Why is erythema infectiosum called the 
“fifth” disease anyway? A Wikipedia article on 
the topic states that “The name… derives from its 
historical classification as the fifth of the classical 
childhood skin rashes or exanthems.”2 In typical 
Wikipedia style, however, no explanation is 
provided. 
 
Even more legitimate resources do little 
else to clarify this issue. Up-to-Date, the bastion 
of evidence-based medicine, notes that “Erythema 
infectiosum is… referred to as ‘fifth disease’ 
since it represents one of six common childhood 
exanthems, each named in order of the dates they 
were first described.”3 But just like its unreliable 
counterpart, Wikipedia, no other details are given. 
 
The purpose of this paper is to: (1) clearly 
describe how and when erythema infectiosum was 
first discovered; (2) explain how and when it 
became known as fifth disease and why this name 
is perhaps inappropriate; (3) describe the 
coincidental discovery of parvovirus B19; and (4) 
explain how the connection between parvovirus 
B19 and erythema infectiosum was finally made. 
 
The discovery of erythema infectiosum 
 
Erythema infectiosum was first described in 1889 
by Tschamer, who thought it represented a milder 
form of rubella (German measles).4 Additional 
cases were described by Gumplowicz in 18915 
and by Tobeitz in 1898.6 According to a review of 
cases presented by Shaw in 1905, the first person 
to suggest that this infection was a separate 
clinical entity was Escherich in 1896.7 
 
This condition didn’t actually become 
known as erythema infectiosum, however, until 
1899, when it was given that name by Georg 
Sticker, a Professor of Medicine at Giessen 
University, Germany.8 Sticker’s description 
included the lack of perceptible fever at the time 
of presentation and emergence of red patches on 
the cheeks, consisting of large symmetrical 
blisters with red halos. The following day, the 
rash spread to the lower arms and thighs, as well 
as over the trunk, forehand, temples. This 
secondary rash consisted of round red spots or 
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larger, irregular, red patches (see Figure 1). 
Sticker noted that these eruptions tended to be 
slightly raised and that they were better felt than 
seen. These symptoms were most apparent on the 
third or fourth day of the infection and then 
rapidly resolved. 
 
 
 
 
 
 
 
 
 
 
Sticker observed how erythema 
infectiosum spread through families and was 
consequently able to confirm its contagious 
nature. He also suggested that it belongs to the 
group of so-called “acute exanthems,” but that its 
particular course and skin symptoms excluded 
any confusion with scarlet fever, measles, or 
rubella (German measles). Sticker’s description of 
erythema infectiosum ends with an interesting 
acknowledgement: “In trying to find the specific 
cause we have been just as unsuccessful as other 
researchers have been with other kinds of kinds of 
infectious exanthems.” Indeed, the medical 
community would have to wait almost a century 
before the causative agent would finally be found.  
 
Sticker’s description of erythema 
infectiosum had such an impact that for many 
years it was known simply as “Sticker’s disease.” 
Even as the term “fifth disease” became more 
common in some parts of the world, the reference 
to the Professor’s name persisted in Germany for 
years to come. 
 
It began with the fourth 
 
The origins of the name “fifth disease” go back to 
1885, when a Russian physician named Nil 
Filatow was working on another childhood 
exanthem. His work was read at the Moscow 
Medical Society meeting on November 20, 1885, 
and later in published in German.9 As with 
Sticker, the list of childhood exanthems 
established up until this time included measles, 
scarlet fever, and rubella (German measles). 
Filatow argued for the existence of a fourth 
exanthem, which he called rubeola scarlatinosa. 
He reasoned that if patients could get this disease 
after having already had scarlet fever, or if 
contracting this disease did not protect them 
against getting scarlet fever in the future, then 
scarlet fever and rubeola scarlatinosa must be two 
different things. Filatow had seen evidence of this 
happening in one set of patients and appealed to 
doctors working in larger institutions to provide 
further evidence for the existence of this clinical 
entity. 
 
One such doctor came along several years 
later named Clement Dukes. Dukes was a 
physician at a Rugby school in London, England, 
where he believed he had seen many patients 
similar to those described by Filatow. In 1894, he 
published an article in the Lancet in which he 
referred to rubeola scarlatinosa as epidemic 
roseola or rose rash.10 (This is not to be confused 
 
 
Figure 1: Classic presentation of erythema 
infectiosum (fifth disease) in a child aged 16 
months. Note the smooth rash on the cheeks and 
lace-like pattern (secondary rash) on the rest of the 
body. 
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with roseola infantilitis, which was described in 
1910 and later became known as sixth disease.11)  
 
Dukes went into great detail describing 
what he believed were clear differences between 
scarlet fever, rose rash, and measles. He conceded 
that “In their elucidation they have entangled 
many of the ablest physicians, to our professional 
discredit and to the detriment of the welfare of 
our schools,” but insisted that “… They are as 
separable as typhus and typhoid fever.” 
 
Dukes published a second article on this 
topic in 1900.12 In this paper, he noted that he “… 
would not venture to suggest an appropriate name 
for this disease,” and referred the question of 
nomenclature to the Royal College of Physicians 
of London. “Pending this authoritative decision,” 
Dukes “… tentatively employ[ed] the general 
expression of the ‘fourth disease.’” Ironically, this 
name not only became permanently associated 
with rubeola scarlatinosa, but it also initiated a 
numbering system for the classic childhood 
exanthems that remains to this day. 
 
The naming of fifth disease 
 
Today, the fourth disease is regarded by most as a 
non-entity.13 In spite of the detailed reasoning 
presented by Filatow and Dukes, other studies 
could not establish that the fourth disease exists 
independently of scarlet fever, measles, or 
rubella, nor could a causative agent be 
determined. The most obvious flaw in the 
Filatow-Dukes logic is the fact that it is possible 
to get scarlet fever more than once.14 Thus, the 
idea that an infection confers immunity, and that 
any future infection that looks like scarlet fever 
must be something else, is incorrect. 
 
Still, the idea of the fourth disease lasted 
long enough for the naming of fifth disease 
several years later. In 1905, a French physician 
named Cheinisse described erythema infectiosum 
in a weekly periodical called La Semaine 
Medical. He made reference to the three classic 
diseases of childhood: scarlet fever, rubella, and 
measles, and mentioned the so-called fourth 
disease, rubeola scarlatinosa, in his introduction. 
His subsequent description of erythema 
infectiosum was entitled “Une cinquème maladie 
éruptive: le mègalérythéme épidémique” (i.e., a 
fifth eruptive disease: the infectious erythema). It 
is unclear when exactly this name was changed to 
simply fifth disease, but the basis of its numbering 
can be traced back to Dukes “general expression 
of the fourth disease” in 1900. 
 
The fact that fourth disease is now 
considered a non-entity suggests that the name 
fifth disease is perhaps inappropriate. While it is 
true that it was discovered after fourth disease, 
this numbering system makes the false 
assumption that Filatow-Dukes’ disease actually 
exists.  
 
The discovery of parvovirus B19 
 
Early attempts to connect erythema infectiosum 
with its causative agent included the inoculation 
of supposedly infected human sera in monkey 
renal cells.15 In another attempt, researchers 
obtained blood samples, throat swabs, and stool 
or rectal swabs from 27 infected patients and 
looked for pathological changes in various tissue 
cultures.16 Neither of these studies were 
conclusive. Another researcher went so far as to 
suggest that the causative agent of erythema 
infectiosum wasn’t infectious at all, but that 
correlation with the use of a margarine emulsifier 
indicated that it was based on nutritional and 
personal factors.17 
 
Given the clinical course of erythema 
infectiosum (see Figure 2), it is easy to see why it 
was so difficult to identify its causative agent, 
parvovirus B19. While it is true that the lifetime 
prevalence of this virus approaches 90%, the 
viremia occurs before the emergence of the 
characteristic, red rash, and then rapidly resolves. 
Furthermore, the symptoms during the prodromal 
period are mild and non-specific. Many other 
cases are asymptomatic throughout the entire 
infection. It should be no surprise then that the 
discovery of parvovirus in human blood occurred 
coincidentally. 
 
The human parvovirus was discovered by 
someone who had no interest in erythema 
infectiosum whatsoever. While working in 
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London, United Kingdom, an Australian 
virologist named Yvonne Cossart came across a 
collection of parvovirus-like particles while 
screening blood samples for hepatitis B.* The 
sample containing these particles happened to 
occupy position 19 on plate B, which eventually 
led to the name B19. 
 
Parvoviruses had long been known to 
infect cats, rats, mice, minks, dogs, pigs, rabbits, 
geese, and cattle.18 But up until Cossart’s 
discovery, there was no evidence for parvovirus 
infection in humans. As a result, researchers were 
initially reluctant to refer to B19 as a true 
parvovirus, opting for terms like human 
parvovirus-like agent (PVLA)19 and human serum 
parvovirus-like virus (SPLV)20 instead. 
 
                                                       
* Cossart later discovered the presence of parvovirus in the 
serum of a patient diagnosed with acute hepatitis. This 
coincidence raised the possibility of parvovirus being the 
elusive non-A, non-B virus. This, of course, turned out to be 
not the case, with hepatitis C being discovered several years 
later. 
Together at last 
 
The search for the causative agent of erythema 
infectiosum was so elusive that it actually ended 
up taking place the other way around. Following 
Cossart’s discovery in 1975, a microbiologist 
named Anderson was busy studying parvovirus 
B19 at King's College Medical School in London. 
In 1982, he noted that “Infection with PVLA 
[parvovirus B19] is an apparently common event, 
occurring most often in childhood. Studies… 
show that that peak of antibody acquisition occurs 
between the ages of 4 and 6 years, and by the age 
of 16 one-third of subjects have PVLA 
antibody…”19 He also noted that “… three of the 
four blood donors from Dr Cossart’s group of 
nine who were followed up became ill shortly 
after giving blood; two complained of fatigue 
which was in one individual accompanied by 
leucopenia, while the third developed a rash.”19 
As seen in Figure 2, these symptoms and sequelae 
are classic to erythema infectiosum. 
 
Figure 2: Schematic representation of the clinical course and laboratory abnormalities in normal hosts with 
parvovirus B19 infection. Note the biphasic timing of symptoms, during the peak viremia and again after the 
viremia has cleared. Rash, arthritis, and other symptoms typically associated with parvovirus B19 occur during the 
second period.2 
 
Prodrome
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In 1983, this same researcher, obviously 
aware of what a parvovirus B19 infection might 
entail, provided epidemiological evidence of a 
parvovirus being the cause of erythema 
infectiosum.21 This connection was aided by a 
coincidental outbreak in north London and the use 
of parvovirus-specific IgM radioimmunoassay to 
confirm true cases.20,22 Further evidence on this 
outbreak was provided in 1984.23 
 
The final confirmation of parvovirus B19 
being the cause of erythema infectiosum occurred 
when seronegative volunteers were inoculated 
with parvovirus from an asymptomatic donor.24 
One week after inoculation, symptoms included 
mild illness, malaise, and other non-specific 
complaints, as well as viremia, excretion of the 
virus from the respiratory tract, and decreased 
levels of hemoglobin, reticulocytes, lymphocytes, 
neutrophils, and platelets. 17 to 18 days later, a 
second-phase of the illness with rash and sore 
joints lasting three days occurred in three of the 
four infected volunteers. (Refer to Figure 2 for an 
overview.) This constellation of symptoms was 
consistent with erythema infectiosum and 
explained why parvovirus infection could cause 
aplastic crisis in patients with chronic hemolytic 
anemia (such as sickle cell disease).   
 
Conclusion 
 
The associations between erythema infectiosum, 
fifth disease, and parvovirus B19 evolved 
gradually over almost 100 years. The turning 
points in this history include: (1) the recognition 
of a “different form of Rubella” by Tschamer in 
1889; (2) the naming of erythema infectiosum by 
Sticker 1899 (and the evidence for its 
independence from scarlet fever, measles, and 
rubella); (3) the influence of Dukes and his 
general expression of fourth disease in 1900; (4) 
the reference to a fifth disease by Cheinisse in 
1905; (5) the discovery of parvovirus by Cossart 
in 1975; and (6) the evidence of parvovirus as the 
causative agent by Anderson from 1983 to 1985. 
 
It is true that some of these details amount 
to little more than historical trivia. But it is the 
authors’ hope that this overview will give 
students a greater appreciation of erythema 
infectiosum, fifth disease, and its elusive 
causative agent, parvovirus B19. 
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Introduction 
 
The recent outbreak of listeriosis has been called 
the worst epidemic of this illness that the world 
has ever seen.1 To date, there have been 53 
confirmed cases across Canada and 20 confirmed 
deaths in which listeriosis has been the underlying 
or contributing cause of death.2 Despite the 
August 24, 2008 recall of over 220 different 
products, concerns of continued spread persist in 
the wake of a November 22 warning from the 
acting chief medical officer of health regarding 
the discovery of Listeria monocytogenes in seven 
provincial correctional facilities.3, 4 Given the 
magnitude of this outbreak, criticisms of the 
responses of all parties involved have been 
inexorable. The Public Health Agency of Canada 
(PHAC), the Canadian Food Inspection Agency 
(CFIA) as well as Maple Leaf Foods and other 
corporations have all been faulted as the toll of 
this outbreak continues to rise.5 Although 
opinions differ where, if at all, blame should be 
laid, most would agree that the listeriosis outbreak 
has given Canadians cause to examine one of the 
most vital areas of collaboration in our health care 
system – the interaction between the various 
organizations which safeguard our food. 
 
Overview of the outbreak 
 
As early as June 2008, Toronto Public Health 
Units noticed a minor increase in the number of 
reported listeriosis cases. By mid-July Toronto 
Public Health increased their investigations after a 
listeriosis case was discovered in a Toronto 
nursing home. Food samples from the nursing 
home were sent to Health Canada labs and on 
August 5, 2008, a sandwich was found to be 
contaminated with Listeria. Toronto Public 
Health then notified the CFIA of the positive food 
samples and on August 12 Maple Leaf Foods was 
informed by the CFIA that a formal investigation 
of their products was underway. CFIA officials 
met with public health officials two days later and 
the decision was made to stop serving certain 
meat products in hospitals and long-term care 
facilities. On August 16 the CFIA and Health 
Canada met and recommended a recall on certain 
Maple Leaf products. The following day Maple 
Leaf announced a voluntary recall of some 
products from their Toronto plant; over the period 
of August 17 – 24 the list of recalled products 
grew to 220 as the number of listeriosis cases and 
associated deaths continued to rise. The recalled 
products also included prepared sandwiches by 
other corporations including Lucerne Meats, 
Atlantic Foods Ltd. and Metro Ontario Inc. 
During this time Maple Leaf Foods’ Toronto 
plant was shut down to undergo cleaning and re-
evaluation of safety practices. The Public Health 
Agency of Canada announced on August 23 that 
tests confirmed the link between the listeriosis 
outbreak to Maple Leaf Foods and the following 
day television ads begin airing featuring Maple 
Leaf CEO Michael McCain’s apologies on behalf 
of the corporation.6, 7  
 
Since then, the Public Health Agency of 
Canada has been continually issuing updates on 
the number of confirmed and suspected cases. 
However, critics of the Ministry of Health and 
Long-Term Care (MOHLTC) and PHAC would 
argue that Michael McCain, rather than acting 
Chief Medical Officer of Health, Dr. David 
Williams or Chief Public Health Officer, Dr. 
David Butler-Jones, has been the major public 
figure informing Canadians about the outbreak.5 
Similarly, critics of the CFIA have lambasted 
2007 reforms that allowed the food industry itself 
a much greater degree of self-monitoring. 
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Considering both the controversy about the 
management of the outbreak and the extent of its 
spread Prime Minister Stephen Harper announced 
an investigation into the outbreak. This 
investigation includes an evaluation of the 
“efficiency and effectiveness of the response by 
federal agencies in terms of prevention, the recall 
of contaminated products, and collaboration and 
communication among partners in the food safety 
system and the public”.1 
  
 The following discussion will examine the 
major agencies involved and review some of the 
criticisms elicited by the epidemic. 
 
The Public Health Agency of Canada and the 
chief public health officer 
 
The Public Health Agency of Canada (PHAC) 
was created in the aftermath of the SARS 
outbreak of 2003. It was initially its own ministry, 
with a cabinet seat reporting directly to the Prime 
Minister. However, in 2006 the government 
eliminated the ministry and cabinet position and 
relegated the Chief Public Health Officer to a 
civil service position under the Minister of 
Health.5 
 
The tasks of the agency include preventing 
both chronic disease and outbreaks of infections. 
The latter task falls primarily under the Infectious 
Disease and Emergency Preparedness (IDEP) 
branch. This branch contains the subdivision 
known as the Centre for Infectious Disease 
Prevention and Control (CIDPC), which is 
responsible for public health surveillance and 
epidemiological studies during foodborne 
epidemics. The National Microbial Laboratory 
(NML) and the Laboratory for Foodborne 
Zoonoses (LFZ) are also involved in outbreak 
surveillance and provide pathogen strain 
differentiation and other analytical services.8 
 
As per the current Canada Foodborne 
Outbreak Response Protocol, the PHAC and 
specifically the CIDPC has the responsibility of 
“communication with the public as it relates to the 
public health implications of the epidemiological 
investigation”, until a food source has been 
identified, at which point the CFIA “will have the 
lead for public communications as it relates to the 
food safety investigation and any necessary food 
safety recall activities”.9 Despite the specificity of 
this protocol, critics have suggested that the Chief 
Public Health Officer failed to act as “the leading 
national voice for public health, [particularly] in 
outbreaks and other health emergencies”.5 Some 
have noted the greater relative prominence of the 
Minister of Agriculture and Agri-Food Canada 
and Michael McCain of Maple Leaf Foods during 
the outbreak. Such criticism has led to concerns 
about the independence of the Chief Public 
Health Officer, who may be constrained by 
prevailing political considerations. As he or she 
serves under the Minister of Health and has less 
protection from dismissal than similar positions in 
the United States and United Kingdom, some 
have questioned this officer’s ability to raise 
public health concerns without fear of political 
repercussions. The independent investigation 
initiated by the Prime Minister will be able to 
assess the efficacy of the PHAC and the Chief 
Public Health Officer given their current 
apparatus and whether the agency acted with due 
diligence. However, new concerns are being 
raised that “the investigator will not have any 
power to subpoena witnesses or documents; the 
investigation will be closed to public 
participation; and there is no commitment to 
publish the investigator’s findings or report to 
parliament”.1      
 
The Canadian Food Inspection Agency and the 
role of industry 
 
The Canadian Food Inspection Agency (CFIA) 
reports to the Minister of Agriculture and Agri-
Food and is responsible for protecting the safety 
of Canada’s food supply. The CFIA implements 
surveillance and inspection programs intended to 
provide an early warning for problems within the 
food supply. In the event of a food safety 
emergency, the CFIA works in partnership with 
Health Canada, provincial agencies, and the food 
industry to operate an emergency response 
system, including food recalls.10  
 
 Inspection of ready-to-eat meat products, 
such as the contaminated cold cuts at the centre of 
the listeriosis outbreak, was formerly done by 
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CFIA inspectors. However, a Canadian 
government review of the CFIA in November 
2007 resulted in various reforms to inspection 
policy. Of particular importance was a decision 
that effectively transferred inspection duties to the 
meat industry, with government inspectors taking 
on more of an oversight role.1 This decision 
meant that inspectors spent less time on plant 
floors conducting visible inspections and more 
time analyzing data collected by industry.11 
Maple Leaf Foods was an early supporter of these 
inspection reforms.1 
 
 The push towards greater industry self-
regulation has not received universal support. 
Those who argue in favour of self-inspection say 
that industry has greater incentives to ensure safe 
products for their customers and are more likely 
to develop new scientific testing technologies and 
protocols.11 Those who argue against self-
inspection say that industry is more concerned 
with profits than product safety. They are 
concerned that tests may not be performed 
adequately, results may be altered, or government 
inspectors may be denied full access to the data.11  
 
 The listeriosis outbreak has affected the 
operations of both the CFIA and Maple Leaf 
Foods. Dr. Brian Evans, CFIA Executive Vice-
President and Chief Veterinary Officer of Canada, 
has conceded that the agency should have done a 
better job communicating with the public during 
the outbreak.12 The CFIA is also revising its 
Listeria surveillance protocols to ensure greater 
transparency and more protection for consumers, 
including reinstating a rule compelling companies 
to inform inspectors of positive Listeria tests.13 
For its part, Maple Leaf Foods estimated the 
outbreak and following recall cost the company 
over $25 million directly and another $14 million 
in lost sales.14 Moreover, the results of a class-
action lawsuit filed against the company are yet to 
be determined. Following the outbreak, Maple 
Leaf Foods toughened its own policies regarding 
Listeria, to a level more rigorous than the 
proposed CFIA protocols.13  
 
 
 
 
Conclusion 
 
Despite the many criticisms of all parties involved 
in the listeriosis outbreak, it remains unclear as to 
where the prevention and response systems failed. 
In fact, it can be argued that all parties responded 
adequately given the circumstances. Further 
investigations by the government may yield 
valuable recommendations to improve the 
response to foodborne illness and the safety of the 
food supply, provided that such investigations are 
thorough, objective, and transparent. However, 
the listeriosis outbreak has already demonstrated 
the importance of rapid communication and 
collaboration between private industry and all 
levels of government to ensure the health and 
safety of the public. 
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In June 2007 a Dutch television station 
broadcasted a program in which a terminally ill 
patient interviewed three potential candidates in 
order to select one of them to receive her 
kidneys.1 The choice of recipient was to be made 
on the basis of the contestant’s history and 
profile, as well as based on conversations with 
their family and friends; viewers were also able to 
add their input via text messages. As expected, 
medical professionals and politicians were 
outraged when the program was aired. Soon after, 
it was revealed that the show was a hoax intended 
to raise awareness about the shortage of organ 
donors; the donor was in fact an actress, while the 
three potential recipients were genuine. Even 
though the impact of the program on the public 
and on government policy is difficult to assess, it 
does bring to our attention the fact that there is a 
significant worldwide shortage in the supply of 
donated organs for those in need.1 In fact, just like 
most other developed nations, Canada has been 
unable to keep pace with the demand for organs. 
This issue of organ shortage is worth exploring in 
order to be able to make conclusions about the 
causes and possible solutions. 
 
The Situation in Canada 
 
In order to assess the extent of the problem in 
Canada it is important to review some of the 
available statistics. For instance, 4,195 Canadians 
were on wait-lists for organ transplants on 
December 31, 20072 compared with 3974 people 
on Jan 1, 2006 and 2592 people in 1995.3 Only 
2188 transplants were performed in 20074 and 
193 Canadians died waiting for an organ 
transplant in the same year.2 Moreover, according 
to the Canadian Organ Replacement Registry, 
Canada’s cadaveric donation rate for deceased 
donors in 2005 was 12.8 per million inhabitants, 
which falls well below the rates in countries like 
Spain (35.1), Estonia (26.5), Belgium (22.8), Italy 
(20.9) and the United States (21.5) as projected by 
the International Registry maintained at the 
University of Barcelona, Spain.3 On the bright 
side, living donation rates in Canada are rising 
and currently stand at 15.6 per million 
inhabitants. Nevertheless, there are significant 
regional variations in deceased and living organ 
donation rates. Deceased donations range from 
5.1 in Manitoba to 17.9 in Quebec. Living 
donations range from 7.0 in Quebec to 19.9 in 
Alberta.3 There are also significant provincial 
variations in wait times for transplants. In fact, a 
recent study of 7034 dialysis patients found 
people under 40 waited a median 8 years in 
Ontario for a new kidney, compared with 3 years 
for those in Alberta.5 Hence, not only does 
Canada have a shortage in organs, the nation also 
possesses a very fragmented system that has led 
to regional variations in organ donation rates as 
well as provincial variations in wait times for 
transplants. 
 
One of the problems of the Canadian 
system is that less than half of the organs that 
could potentially be transplanted are actually 
harvested. There are a number of reasons for the 
inefficiency including the fact that in many cases 
the family members of an individual are simply 
not approached for consent. In addition, there is 
no concerted effort and little resources allocated 
to educate Canadians about the benefits of organ 
donation.4 However, the main problem with the 
Canadian system lies in the presence of many 
fragmented organ donation programs that are so 
varied that it is difficult if not impossible to 
characterize national practice in Canada as a 
whole.3 The existence of many organizations and 
programs that vary from province to province is a 
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“reflection of the fractured jurisdiction over 
health care”.3 In fact, it has been suggested that 
Canada’s low organ donation rates maybe be 
partly due to a lack of a coordinated and 
centralized approach to dealing with the issue.3  
 
New Developments 
 
In recent months there have been attempts by both 
federal and provincial governments in Canada to 
make policy changes that will reduce the shortage 
of organs available for transplantation by 
attempting to decrease the fragmentation and 
improve the coordination and communication 
amongst the provinces. In fact, one very recent 
positive development with regards to organ 
donation in Canada was an agreement reached in 
August 2008 between the federal, provincial 
(except Quebec) and territorial governments to 
develop an “integrated national organ donation 
system” 6, including national oversight and 
allocation mechanisms for all donated organs and 
tissues. Prior to this initiative, Canada was the 
only developed country without a national 
transplant system, which has resulted in a 
significant variation in organ donation rates 
across the country and a lack of equal access to 
life-saving transplants.4 Under the new funding 
arrangement, the Canadian Council for Donation 
and Transplantation (CCDT) has merged with 
Canadian Blood Services, which has expanded its 
mandate and operations to include organ and 
tissue donation and transplantation.2 While the 
fragmented provincial transplantation agencies 
will continue to run independently, more effort 
will be put into improving the co-ordination 
amongst the different agencies.  
 
The initiative is further aimed at creating 
and managing three electronic registries: the 
Urgent Status Registry to ensure patients most 
desperately in need of organs are treated first, 
regardless of where they live; the Living Paired 
Exchange Registry to facilitate the donation of 
organs such as kidneys and lungs by living 
donors; and the Intent to Donate Registry to co-
ordinate the various provincial programs that 
allow potential donors to give their consent to 
donate organs when they die.4 The creation of 
these registries will not only reduce the 
fragmentation in our approach to organ donation, 
it will also provide us with much needed data and 
evidence to allow us to better evaluate our 
progress. In addition to the national organ-sharing 
network that will be created, there will also be 
efforts directed at standardizing consent policies 
and creating nationwide wait lists for all available 
organs. Mandatory organ sharing and other 
requisite elements of a national organ donation 
and transplantation program will be phased-in 
over a number of years.6 
 
Alternative options 
 
At the present time, Canada utilizes an “opt-in” 
approach to organ donation. An individual needs 
to give consent by signing an organ donation 
card, or explicit consent needs to be obtained 
from surviving family members before a person’s 
organs can be used after their death.3 This 
approach to organ donation has proven to be 
suboptimal when it comes to harvesting organs to 
give to those in need. In fact, Canada possesses a 
legal framework that does not promote organ 
donation.  
 
An alternate strategy would be a 
“presumed consent” (opt-out) approach, whereby 
everyone is presumed to be a donor unless they 
have specified otherwise in advance.3 There are 
two main variations of this policy that have been 
utilized in some European countries.  For 
instance, Spain, a world leader in organ 
donations, has managed to achieve the highest 
organ donation rate in the world by implementing 
a policy of “soft” presumed consent whereby 
relatives may opt-out for a dying patient.7 In 
addition, the Spanish government invested 
heavily in educational campaigns and “transplant 
support teams”7 who provide emotional support 
to bereaving families, helping decrease refusal 
rates. Since the implementation of the “soft” 
presumed consent approach in Spain in 1990, 
donation rates have doubled to their current level 
of 35 per million. Another variation of this policy 
is the “hard” presumed consent policy seen in 
Austria where relatives may not opt-out for a 
dying patient. This approach began in Austria in 
1982, and since then, their donation rate has 
quadrupled to 25 donors per million.7 Ontario 
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rejected the presumed consent approach on the 
grounds that Canadian society “is not ready”3; 
however, it is difficult to say whether or not the 
government has the right to judge if the people 
are or are not ready for a new approach to organ 
donation. Still the Ontario government is not 
sitting idle and is considering the idea of “first 
person consent”, whereby an organ is 
automatically harvested when a donor card has 
been signed, with no consideration for the opinion 
of the donor’s family.3 
 
As effective as presumed consent appears 
to be, however, simply changing organ donations 
laws and regulations will not solve Canada’s 
shortage of organs. What is needed in addition to 
changing the laws is a significant shift in attitudes 
toward organ donation. In Spain for instance, 
considerable emphasis is placed on organ 
donation awareness. There is special funding and 
training provided for transplant teams, who are 
responsible for working with grieving family 
members to explain the situation and explain to 
them the value of organ donation. Furthermore, 
the general public needs to be educated about the 
importance of signing their organ donation cards, 
and about the many lives they can save if they 
choose to do so.  Without such a system of 
education and counseling for grieving families, a 
presumed consent law will not live up to its 
potential.7  
 
In addition to presumed consent, there are 
a number of other strategies that can possibly be 
implemented to address the shortfall in donated 
organs. These include monetary incentives for 
those who signup to be a donor. For instance, 
making an offer to the family to reimburse the 
donor’s funeral expenses. Other incentives could 
include providing priority access for previous 
donors in the event they need an organ.3  
 
Conclusion and Future Outlook 
 
All in all, Canada has had a dismal record when it 
comes to organ donation and that must change 
sooner rather than later because the demand for 
organs has been growing over the years. The 
federal and provincial governments have taken 
some positive steps in recent years to try to 
improve the situation; the most significant step 
has been the plan to develop an integrated 
national organ donation system, including 
national oversight and allocation mechanisms for 
all donated organs and tissues. However, more 
needs to be done to correct the current state of 
affairs. This could involve amending the current 
laws and regulations pertaining to organ donation, 
educating the public and raising awareness about 
the importance of organ donation, as well as 
providing incentives for those who agree to 
donate their organs. Until such time we can only 
look with admiration towards countries such as 
Spain, which has become a world leader when it 
comes to organ donation.  
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Nanotechnology is a major recent technological development affecting medical approaches to disease 
treatment and immunity induction. For example, nanoparticles can be used to create anti-microbial agents 
and vaccine adjuvants to target difficult microbes such as HIV, Salmonella, Tuberculosis and Listeria. 
While this new technology makes lofty promises, it is important to keep in mind the possible biological and 
environmental hazards of nanoparticles. In the coming decade, physicians will be called upon to make both 
treatment and policy decisions regarding the use of nanoparticle technology. 
 
Introduction 
 
For those who are not “nanotechnology” 
scientists, the word appears to be much of an 
enigma, conjuring up science fiction style images 
of micromachines, computer chips and 
lithography. Richard Feynman may not have been 
thinking about battling infectious diseases when 
he coined the famous quote “There's plenty of 
room at the bottom”, but there is certainly plenty 
of room for nanotechnology in our campaign 
against microbes. 
 
Despite the fact that nanotechnology is 
rapidly changing the face of medicine, many 
physicians are still unable to define it. The US 
National Nanotechnology Initiative defines 
“nanotechnology” as “understanding and control 
of matter at dimensions of roughly 1 to 100 
nanometers, where unique phenomena enable 
novel applications”.1 In the past, engineers were 
confined to using naturally occurring materials 
and forming them through industrial processes. 
Material properties frequently constrained device 
designs. Nanotechnology allows materials to be 
custom-designed on a molecular scale and enables 
the design of new and different devices. 
 
Like much of medicine, our battle with 
infectious disease has been one of broad sweeps 
because it is difficult to target microbes and 
components of the immune system with high 
specificity. Treatment has been caught in a 
perpetual tug of war attempting to balance the 
dangers of illness against the damage incurred by 
therapy. The immune system is a perfect example 
of molecular machinery at its most complex. 
Nanotechnology provides the opportunity to meet 
microbes and our immune systems at a molecular 
level. While there are many potential applications 
for nanotechnology in the area of infection and 
immunity, some of the earliest and most 
promising developments have been in the 
development of antimicrobial agents and new 
vaccines. 
 
Antimicrobial Agents 
 
Nanoemulsions are oil-in-water droplets ranging 
from 200-600 nm2. These are high energy 
droplets thermodynamically driven to fuse with 
lipid-containing organisms.  The electrostatic 
attraction between the cationic charge of the 
emulsion and the anionic charge on the pathogen 
enhances the fusion. When fusion occurs, the 
active ingredients inside the particle and the 
energy released in the fusion process destabilize 
the lipid membrane, resulting in cell lysis and 
death. These antimicrobial agents can be used in 
wound irrigation and decontamination of high-
risk surfaces (for example in hospitals). Studies 
have shown these agents to be effective against 
bacteria (E. coli, Salmonella, S. aureus), viruses 
(HIV, Herpes), and fungi (Candida).2 
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Nanoparticles are also used to deliver 
antimicrobial agents. A microscopic carrier hides 
and protects molecules from degradation in the 
body, and allows it to be delivered to specific 
target cells in a controlled manner.3 Alternatively, 
special “carriers” can be designed to carry 
therapeutic agents across membranes into specific 
intracellular compartments and through the blood-
brain barrier. These areas  have traditionally been 
difficult to reach.4  Research in this area began in 
the early 1990s, and has since expanded to 
encompass treatment of many intracellular 
infections, including fungal and parasitic 
infections, Listeria, Salmonella and 
Tuberculosis.5,6 Nanoparticle carriers can be 
metallic, lipid-based, polymer-based or biologic 
(resembling a virus).6 
 
Silver particles have long been known to 
be bactericidal. Recent research on silver 
nanoparticles have demonstrated them to be quite 
promising against new strains of bacteria resistant 
to current antibiotics, and gram negative bacteria, 
including E coli, V cholera, P aeruginosa, and S 
typhus. The bactericidal properties of 
nanoparticles are size dependent, with particles 1-
10nm having the best direct interaction with 
bacteria. Silver nanoparticles act primarily in 
three different ways. Nanoparticles attach to the 
surface of the cell membrane and disturb its 
function, rhey penetrate the bacteria and interact 
with DNA, and they release silver ions which 
have a separate bactericidal effects.7 
 
Vaccine Development 
 
The effectiveness of a vaccine is measured by its 
ability to interact with, and stimulate, the immune 
system. The nano-engineering of vaccines allows 
the creation of better adjuvants and vaccine 
delivery systems. Currently, nanoparticles are 
being used in the design of nasal and 
transcutaneous vaccines. A nasal vaccine attempts 
to generate an immune response by exposing the 
nasal mucosa to antigens. Similarly, 
transcutaneous vaccines target the immature 
dendritic cells (professional antigen-presenting 
cells) found in high density in the epidermis and 
dermis of the skin.  
 
Traditionally, nasal vaccines have had 
limited effectiveness because free antigens are 
readily cleared from the nasal cavity, poorly 
absorbed by nasal epithelial cells, and generally 
have low intrinsic immunogenicity. Encapsulation 
of the antigen into bioadhesive nanoparticles will 
allow these particles to be tailor-made with 
specific ligands, adjuvants and endosomal escape 
mediators. Some of the promising nasal vaccines 
underdevelopment include vaccines for: 
Parainfluenza, Hepatitis B, Measles, Yersinia 
pestis, and HIV.8, 9, 10, 11  
 
Particular attention is being paid to the 
HIV vaccine. Since HIV targets immune cells in 
an unusual way, standard approaches to an HIV 
vaccine have been met with limited success. 
Vaccines administered in the nose to induce 
mucosal immunity are also able to induce 
immunity in the genital mucosa. Development of 
mucosal immunity may play an important role for 
protection against HIV, as it allows the body to 
mount an immune response early on in the disease 
process.8 The production of IgA antibodies on 
mucosal surfaces is unique to mucosal 
immunization. Mucosal immunization will 
stimulate both the mucosal and systemic immune 
responses (systemic immunization will only 
induce the systemic response), improving vaccine 
efficacy.12 
 
Current transcutaneous particle-based 
vaccines are made of naturally occurring 
“particles” and can vary in quality from batch to 
batch and induce adverse events. Manufactured 
nanoparticles can be topically applied to hair 
follicles.13 In a similar fashion to the nasal 
vaccine, this technique uses nano-sized inert solid 
carrier beads to covalently bond antigen.14 
 
In both the nasal and transcutaneous 
vaccines, particle characteristics are important 
determinants of the effectiveness of the vaccine. 
Nanoparticles allow particle characteristics to be 
designed to specification. It also allows for a 
systematic study of the effects of parameters such 
as particle size, shape, and charge.15 
Nanoparticles approximately 10m in diameter 
are selectively uptaken by cells in Peyer’s patches 
in the gut. It is postulated that particles 
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resembling the size of viruses will trigger a viral-
type immune response (cellular), whereas 
particles the size of a bacterium are more likely to 
trigger a humoral response. Smaller nanoparticles 
are also more rapidly absorbed by nasal mucosal 
cells. Since epithelial cells carry a negative 
charge, a positively charged nanoparticle should 
be more effective than a negatively charged 
particle.16  
 
With all the hype surrounding 
nanotechnology, physicians need to be prepared 
to address patient concerns regarding the new 
vaccine designs. Some questions they should be 
prepared to answer include: Are these vaccines 
fundamentally different from those used in the 
past? What potential problems may arise from 
their use? How do they differ, in terms of risks, 
effectiveness and adverse events from other 
vaccines? 
 
Other applications 
 
With clinical applications of nanoemulsions and 
nanoparticle vaccines already in use, it is not 
difficult to imagine other potential applications of 
nanotechnology in immunology. Drug delivery 
systems designed to interact with tissue in 
specific locations and times are currently being 
used in engineering. These systems should allow 
for more accurate targeting of therapeutic agents 
– allowing greater therapeutic effects through 
increased activity, and decreased adverse effects. 
These medications take advantage of the ability to 
control molecular structure to allow for enhanced 
activity.16 Perhaps most fantastic of all is the idea 
that scientists may eventually be able to create 
special pieces of machinery that imitate the 
immune system to destroy specific targets, in 
essence manufacturing artificial “antibodies” that 
can be administered to patients as anti-microbial 
agents.17 While these prospects may appear to still 
be speculations of the future, it is not too early for 
physicians to be preparing for their eventual 
integration into mainstream medicine. 
Pharmaceutical companies are already actively 
pursuing and preparing for this major change in 
how therapeutic agents will be delivered and 
work. Published patent applications in this area 
have increased at a near exponential rate in the 
past 10 years, and this is expected to continue 
well into the future.18 Most significantly, the 
Nanomedicine Initiative of the National Institutes 
of Health Roadmap for Medical Research 
initiative predicts that nanomaterials will begin 
yielding significant medical benefits within the 
next 10 years.19 Diagnostic application of 
nanoparticles are also important for rapid 
treatment to some infections. 
 
Nanotechnology – Friend or Foe? 
 
While nanotechnology holds a lot of promise, it is 
important not to overlook the potential problems 
and hazards that this technology may pose. The 
creation of new materials may impart unintended 
novel chemical properties that may be harmful to 
human health. These may be difficult to identify 
in short-term clinical trials.20 In recent years, the 
significance of nanotoxicology has started to 
become recognized and studied. Nanotoxicology 
has developed into its own emerging discipline, 
including its own international conference, 
NanoTox, which emerged in 2007 to study the 
potential problems arising from the use of nano-
sized particles, materials and machines, and 
potential solutions.21 Another recent study from 
the Woodrow Wilson Centre's Project on 
Emerging Technologies concluded that there is 
limited understanding of the effects of 
nanotechnology on human health.22 Physicians 
will have a significant role in the management of 
these problems. 
 
There are also major political, economical, 
environmental and social ramifications associated 
with this technology. For example, the small size 
of particles, combined with potentially novel 
chemical properties, poses a question of how 
ingested but non-metabolized particles may be 
collected and properly disposed of. In addition, 
the effects of such particles on the environment, 
and the environmental impacts of production 
processes have not been adequately studied.23 As 
a major stakeholder in nanovaccines and 
nanoemulsions, physicians will be looked upon 
by governmental and regulatory agencies to 
comment on the balance of benefit and hazards 
posed by these materials. 
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Developments in nanotechnology have 
opened up many new approaches to treating and 
preventing infectious disease. Nanoparticle anti-
microbials and vaccines are examples of how this 
new technology is likely to be used in the coming 
decade. Physicians will have a major role in 
policy-setting, technology implemention and 
answering the questions of a concerned and 
curious public. 
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“Part of what drives people in infectious diseases is that we find some international and tropical diseases 
just fascinating… We’re often people who like details, we’re good at trivial pursuit – that’s just the nature 
of who we are.  Part of what drives us is that there really are no borders in the world, and disease does not 
stop at a border.  There is a famous quote that says, ‘There is nowhere anymore from where we are distant, 
there is no place that is remote.’ Infectious diseases affect all of us.” 
 
Dr. Marina Salvadori is passionate about fighting 
infectious diseases, and with good reason. 
Infections have been a driving force of history in 
fields as diverse as politics, economics, and art.  
Alexander the Great died prematurely of a lung 
infection, the bubonic plague contributed to the 
shift away from European feudalism, and 
tuberculosis helped to shape the Romanticist 
movement.  Part of the tried-and-true fabric of 
medicine, in Dr. Salvadori’s words, Infectious 
Disease is “about advocacy, about global health, 
about “stamping out disease and pestilence.” 
 
Dr. Salvadori is a pediatric infectious 
diseases specialist active in advocacy work, with 
a particular focus on the promotion of 
vaccinations. Her medical career started in the 
Queen’s University medical class of 1991, which 
she followed with a pediatrics residency in 
Winnipeg: 
 
“I decided when I was about 12 that I 
wanted to be a doctor, probably because I 
absolutely loved my family doctor.  I 
thought he was the most wonderful person 
in the world and I just thought it would be 
such a fun thing to do.  I also was raised in 
a family that had a tremendous sense of 
social justice and social responsibility, so I 
knew my final career choice had to have an 
aspect like that… 
  
At first I did pediatrics, and I think that was 
because I grew up in an immigrant family 
and had no cousins or grandparents or 
anything, so the oldest people I knew were 
my parents, who were 46 when I went to 
medical school… When I did pediatrics I 
felt a sweeping sense of relief.” 
  
It may reassure current medical students and 
residents that, while she is happy in her current 
work, her choice of careers was not without a few 
bumps along the road: 
 
“Once I was in pediatrics I realized that I 
had very poor technical skills and I’m not 
good with my hands, which I did know 
beforehand, but it was emphasized in 
pediatrics!  I’m what I call a cognitive kind 
of doctor. … If I had known about 
community medicine and public health, I 
may well have done that.” 
 
When asked about a typical day, she responds that 
answering such a question is impossible: 
 
“That’s what I like about being a pediatric 
infectious diseases specialist – the fact is 
there actually is no such thing as a typical 
day! By the nature of infectious diseases, 
most things are very acute, so when I get up 
in the morning I have no idea what I’m 
going to have to deal with that day… On a 
given day I can’t predict my patient load, I 
can’t predict what kinds of problems I’m 
going to see, and that is partly why I do 
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academic medicine and why I do infectious 
diseases.  
 
I do various things… teaching medical 
students and residents, teaching other 
health care professionals, interfacing with 
public health on policy development, 
working on national advisory committees 
for immunizations, traveling… What’s most 
rewarding is when I’m part of national and 
provincial decision-making that comes out 
with a policy that actually has a huge 
health impact that nobody sees or knows 
about.” 
 
Such contributions include advocating for the 
infant pneumococcal vaccine for Ontario–a 
relatively low-profile health policy change that 
has nonetheless had a significant impact on health 
for all.  Dr. Salvadori’s work consists of a 
remarkably diverse collection of endeavours, 
including some international health initiatives: 
 
“I’ve had some fabulous opportunities.  I 
joined a group from UBC and did some 
teaching of pediatric infectious diseases 
doctors in China, because they don’t have 
infectious diseases as a specialty, and after 
SARS thought they should.  A large Hong 
Kong donor asked that Canada be part of a 
training program for these people.  I went 
there to teach and some of them have come 
here, and that was a wonderful experience.  
I’ve also been asked to do policy 
development for a pediatric oncology 
hospital in Egypt, because they’re trying to 
get a pediatric oncology care for the Arab 
world.  They needed someone to help adapt 
policies to their situation, and that was 
really interesting.” 
 
Dr. Salvadori continually emphasizes the need for 
“big picture” thinking in medicine. When asked 
about challenges she faces on an individual basis, 
she comments not on obstacles associated with 
patient care, but on policy issues.  In particular, 
she highlights the importance of developing 
nationally driven policies rather than fragmented 
provincial guidelines, and alternative financing 
models that encourage physicians to be involved 
in advocacy and preventative medicine. She also 
comments more broadly on the challenges facing 
the world of infectious diseases: 
 
“There are so many.  There’s the HIV 
epidemic, which is changing the political 
and economic landscape of Africa.  There’s 
tuberculosis coming out as multi-drug 
resistant.  There’s global warming, which is 
dramatically affecting the habitats of 
animals and then changing how the 
microbes they carry interface with humans, 
so we’re getting all kinds of new infectious 
diseases emerging…. If you look at a global 
picture, infectious diseases are still the 
number one killer of people and the number 
one health care issue.  If you look at our 
very privileged North American society, 
infection control is becoming more and 
more paramount in hospitals, as are 
infection-related illnesses from drug 
resistance.”   
 
I also have to say that the implementation 
of vaccination programs with growing 
groups of vaccine naysayers, who could 
actually lose all the ground we as a society 
have gained in the fight against infectious 
diseases, is a huge challenge…. There are a 
lot of challenges, and certainly a lot of 
work to be done.” 
 
Nonetheless, she has high hopes for the future, 
and a firm belief that there will be world changing 
scientific advances within this generation: 
 
“Another rewarding aspect [of my work] is 
vaccine evaluation and development that 
has the potential—and I know this sounds 
grand—to change the face of disease in the 
whole world.  The Human Papilloma Virus 
vaccine and cervical cancer is one such 
vaccine.  Rotavirus vaccine is another.  We 
lose 600,000 children in the world a year 
and now that vaccine has been developed.  
To be part of guidelines for its use really 
makes me feel that we can have a local, 
provincial, national, and global impact…. 
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We’re doing very well.  AIDS in Africa is 
really difficult, but there will be an effective 
vaccine.  It will happen.  We all want it 
tomorrow, but if it’s in 20 or 30 years, 
that’s a very small timeframe in the history 
of the world. I think it will be before that, 
and then we can really make a difference.  
When you look at it, vaccination is the only 
thing that we as a global community 
endeavour to at least offer to every global 
citizen.  There is nothing else.”  
 
Many infectious disease specialists see global 
health as an essential obligation as well as a way 
to re-ignite their initial passion for their field. Dr. 
Salvadori sees new possibilities in this area as a 
result of increased funding:  
 
“I look to some of my colleagues, who in 
the latter part of their careers, do fantastic 
projects with the World Health 
Organization.  They’ve done immunization 
implementation that’s rational and that you 
can apply to the local culture and situation.  
I’m really inspired and driven by that kind 
of work.  I tell people that before the 
internet and computers—before any kind of 
mass communication—we as a global 
community eradicated smallpox.  We can 
do that for other diseases, like polio, and 
we actually can conquer these as 
humankind. 
 
The Bill and Melinda Gates Foundation has 
the largest impact in the infectious diseases 
world, particularly in developing nations 
and immunization initiatives, of anyone 
else.  They have given $800 million a year, 
which is the exact same budget as the 
World Health Organization.  Some of my 
colleagues who have toiled away in 
unknown parts of Africa on obscure 
diseases with $20,000 grants have now 
been able to make huge steps forward.  For 
these people, it wasn’t intellect, drive, or 
ability, but money that stopped them from 
reaching their potential.” 
 
In sum, both abroad and at home, Dr. Salvadori 
seeks to fulfill the dual roles of the physician as 
health care provider and patient advocate:   
 
“For me, being an infectious diseases 
doctor, advocacy and patient care are so 
intertwined, and so much a part of what I 
do.  Advocating for appropriate 
immunization schedules for infants actually 
takes care of my patients as a whole 
because then they don’t get infectious 
diseases.  I cannot separate my professional 
roles of advocacy, teaching, and immediate 
patient care on an individual level because 
they’re so intertwined in who I am and how 
I practice medicine.” 
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Case 
 
Accompanied by his mother, seven-year-old John 
presents with worsening non-productive cough 
and fever.   Two days ago, he was diagnosed with 
an upper respiratory tract infection at a walk-in 
clinic and prescribed amoxicillin; however, his 
condition did not improve.  His past history is 
negative for allergies, asthma, cardiovascular 
disease, and cancer. However, his mother recalls 
about 5 similar episodes over the years. John was 
born at term, and his immunization is up-to-date.   
 
On physical exam, his oral temperature is 
38.2oC, his heart rate is 95 beats per minute, his 
respiratory rate is 35 breaths per minute, and his 
blood pressure was 100 over 60 mmHg. The child 
is occasionally coughing, but does not appear 
toxic.  
 
A chest radiograph revealed left lower 
lobe consolidation consistent with a diagnosis of 
pneumonia. John was treated with clarithromycin 
and improved over the next two days.   
 
Etiology/Causative Agents     
 
Pediatric pneumonia is a significant cause of 
morbidity and mortality worldwide causing two 
million deaths yearly.1-5 In North America, the 
annual incidence of pneumonia ranges from 15 to 
45 per 1000 children, depending on the particular 
age group. Although not a major cause of 
mortality in North America, pneumonia in 
children is a major source of morbidity. 
  
In planning therapy knowing the 
responsible pathogen is a key element in 
designing the therapeutic plan.  The best predictor 
of the causative agent is age (Table 1).6-8 
However, even in prospective research studies, 
the pathogen could not be identified in half of the 
cases, and in the clinical setting blood cultures of 
children with pneumonia are commonly negative. 
As the determination of the causative pathogen is 
difficult, empirical therapy is the common 
treatment course for children with pneumonia. 
 
 
 
Table 1: Causative agents based on age group.  
Age  Causative agents (in descending order of frequency) 
Birth to 20 days Group B streptococci, gram-negative enteric bacteria, cytomegalovirus, Listeria 
monocytogenes 
 
3 weeks to 3 months Chlamydia trachomatis, respiratory syncytial virus, parainfluenza virus 3, 
Streptococcus pneumoniae, Bordetella pertussis, Staphylococcus aureus 
 
4 months to 4 years Respiratory syncytial virus, parainfluenza viruses, influenzavirus, adenovirus, 
rhinovirus, Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma 
pneumoniae, Mycobacterium tuberculosis 
 
5 to 15 years Mycoplasma pneumoniae, Chlamydia pneumoniae, Streptococcus pneumoniae, 
Mycobacterium tuberculosis, influenza A or B, adenovirus, other respiratory viruses  
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Risk factors 
 
Risk factors that increase the incidence or severity 
of pneumonia in children include: prematurity, 
malnutrition, low socioeconomic status, 
attendance at day-care centers, passive exposure 
to smoke, pollution or toxic fumes.9 Inhalation of 
harmful substances contributes to lung 
inflammation and damages cilia function, thereby 
reducing the ability of the lungs to clear 
themselves, thus making them more prone to 
infection. Also, children whose immune systems 
are compromised by illness, immunosuppressant 
drugs or chemotherapy have a higher risk of 
contracting infections.10 
 
Clinical Assessment 
 
Pneumonia should be suspected when a child 
presents with fever and one or more signs of 
respiratory distress including grunting, nasal 
flaring, rales, retractions, wheezing or 
tachypnea.11 It has been suggested that tachypnea 
is the best indicator a child has pneumonia rather 
than an uncomplicated upper respiratory tract 
infection.12 The most commonly used guidelines 
for assessing tachypnea are that of the World 
Health Organization’s and are as follows: for 
children one to five years of age a respiratory rate 
of more than 40 breaths per minute and in 
children older than five years more than 30 
breaths per minute signifies tachypnea.13 
Measurement of tachypnea requires a one full 
minute count while the child is quiet. Pneumonia 
is unlikely in patients without fever and more than 
one respiratory sign.14 In patients with respiratory 
distress but no fever, a reactive airway disease, 
aspiration of a foreign body, or underlying 
pulmonary or cardiac disorder should be 
considered. 
 
It should be mentioned that classically two 
presentations have been described for pneumonia:  
 Typical pneumonia: fever, chills, pleuritic 
chest pain and a productive cough. 
 Atypical pneumonia: gradual onset over 
several days to weeks, dominated by 
symptoms of headache and malaise, 
nonproductive cough and low-grade fever. 
 
However, clinically it is often difficult to 
distinguish between these two presentations. 
Also, it is not possible to distinguish whether the 
cause of pneumonia is viral or bacterial based on 
clinical signs alone.15 
 
Diagnosis and Testing 
 
The main support for a diagnosis of pneumonia 
comes from the patient history and physical 
examination. A chest radiograph is considered by 
many to be the gold standard for confirming a 
diagnosis of pneumonia.16 However, there is some 
controversy regarding the utility of using chest x-
rays to distinguish between causative organisms. 
Classically lobar infiltrates were associated with 
bacterial infections and interstitial filtrates are 
thought to be indicative of viral infections. 
However, both lobar and interstitial filtrates have 
been found in viral, bacterial and viral-bacterial 
infections. Some studies flatly state there is no 
relation between the appearance of the chest x-ray 
and the causative agent.17 Whereas, others claim 
there is some value in using radiological features 
to distinguish between bacterial and viral 
etiologies.18 
 
When additional information is required to 
help decide whether antibiotics are necessary a 
WBC and differential count may be useful.19 The 
pneumonia is likely of bacterial origin if the WBC 
count is elevated (typically greater than 15 000) 
with predominance of polymorphonuclear cells.20 
If the child is more than 10 years of age and is 
able to produce sputum a Gram stain test and 
culture of the sputum can be used to help identify 
the cause.21 For Mycoplasma and Chlamydia 
species serologic testing for IgM or increase in 
IgG titres may be useful.22 However, serologic 
testing is often of little use in the immediate 
treatment a patient, and usually provides only a 
retrospective diagnosis to determine the cause of 
an outbreak.  
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 In most children with community acquired 
pneumonia identification of the causative 
organism is not critical. However, in cases where 
the patient has severe symptoms, is not 
responding to treatment or if there appears to a 
community outbreak, the responsible organism 
should be determined. 
 
Management 
 
As mentioned above, identifying the causative 
agent is difficult. Thus, the current Canadian 
guidelines for the treatment of Paediatric 
pneumonia, established in 1997, approach the 
problem from an age based, etiologic 
perspective.23 
 
The consensus group suggest therapy 
based on age and the most common causative 
agents. They favoured antibiotics with the 
cheapest price, narrowest spectral range, 
minimum side effects, and ease of compliance. 
These guidelines allow for flexibility based on the 
overall clinical presentation, and the local 
resistance patterns of predominant bacterial 
pathogens. The consensus groups add that the 
scarcity of well-conducted randomized controlled 
trials make their recommendations weak.   
 
 Most moderate forms of pneumonia could 
be treated with oral agents, while intravenous 
administration is reserved for patients with severe 
pneumonia requiring hospitalization. Children age 
less than 6 months, children with toxic 
appearance, children requiring supportive therapy, 
or children not responding to oral antimicrobial 
therapy should probably be admitted to the 
hospital. The recommended therapy based on age 
group and pneumonia severity is summarized in 
Table 2. 
 
An important part of treatment is 
supportive care, including hydration, antipyretic 
therapy and oxygen as necessary.  As well, the 
child should be monitored and follow-up arranged 
to determine if therapy has been successful or if 
therapy needs to be re-evaluated. 
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Extrapulmonary manifestations of tuberculosis (TB) are an uncommon but important disease entity.  
Genitourinary (GU)-associated infections in particular occur mostly secondary to those of the lungs, but can 
also occur as primary infections through infected clothing or even via sexual transmission. Two case 
reports, one of a man with a cutaneous penile tuberculous ulcer, and the other of his wife who later 
contracted endometrial TB, illustrate the latter route of transmission.  While penile ulcers in men and 
infertility in women have long differential diagnoses, it is important to keep in mind that extrapulmonary 
TB is a possibility, especially in patients from TB endemic areas.  Investigations of these disorders should 
therefore include a full TB workup in patients in whom TB is a possibility, including Mantoux testing, 
histopathology looking for caseating granulomas, and chest radiography to differentiate between primary 
and secondary genitourinary TB.  Given the serious complications of genitourinary TB, including sexual 
dysfunction in men and infertility in women, it is extremely important to effectively recognize and treat GU 
manifestations of TB. 
 
Introduction 
 
Although the majority of primary tuberculosis 
(TB) occurs in the lungs, approximately 20% of 
infected patients will develop an extrapulmonary 
manifestation over time. The genitourinary (GU) 
tract is the most common site for extrapulmonary 
TB, with the most frequently affected sites within 
the GU tract being the epididymis (42%), seminal 
vesicles (23%), prostate (21%), testes (15%) and 
vas deferens (12%) in males, and the fallopian 
tubes in females.1,8 The first cases of 
genitourinary TB were described in the 19th 
century, in which they occurred as a complication 
of routine infantile circumcision, after which TB-
infected surgeons sucked the bleeding penis, thus 
transmitting the disease to the infant. Now 
however, other methods of transmission to the 
GU tract are being described. 
 
Amongst all GU-associated TB infections, 
penile cutaneous TB is extremely rare, 
comprising less than 1% of all cases in males.2 It 
may manifest as primary, secondary, or 
papulonecrotic tuberculide type. Primary 
infection may be acquired by direct inoculation of 
the mucosa through contaminated skin or 
clothing. Secondary infection, on the other hand, 
refers to disseminated TB occurring after 
infection of other organs in the genitourinary 
system or arising from haematogenous spread 
from the lungs. Lastly, papulonecrotic tuberculide 
type is a subset of secondary infection, 
representing an allergic reaction to bursts of TB 
antigen reaching highly immune-sensitive skin 
following haematogenous spread from an internal 
nidus (such as the lungs).4 Of the three types of 
transmission, primary is thought to be the most 
rare. Sexual transmission has been recognized as 
a legitimate mode of primary spread with 
important implications for reproductive health, as 
demonstrated by the following case reports.3   
 
Case 1 
 
A 50-year-old Indian man living in the United 
Kingdom presented with a painless, indurated 
ulcer near the penile corona after a recent trip to 
India.  The lesion had been present for two 
months and had increased in size to measure 1 cm 
in diameter and 1 cm in depth at the time of 
examination.  Left inguinal lymph nodes were 
palpable and non-tender, but no additional local 
or systemic symptoms were present.   
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Investigations began with a punch biopsy 
that was negative for penile carcinoma, however 
granulomas of an unknown cause were revealed.  
Urine tests, chest radiograph, and abdominal 
ultrasound were unremarkable.  The patient did 
not consent to HIV testing, but stated that his wife 
had been his only partner for the past 25 years.  
An excisional biopsy demonstrated the presence 
of caseating granulomas which produced 
Mycobacterium tuberculosis on culture. 
 
The initial treatment regimen was 
combination therapy of isoniazid, rifampicin, 
pyrazinamide, and pyridoxine for two months.  
Isoniazid and rifampicin were then to be 
continued for an additional four months.  The 
ulcer regressed and did not recur.  Although 
screening conducted by the Public Health 
Department in Oxfordshire could not uncover 
other cases of TB in the patient’s family, the 
patient’s wife did not consent to genitourinary 
screening.   
 
Case 2 
 
The 49-year-old wife of the patient in Case 1 
presented with menorrhagia, fever, sweats, and 
weight loss one year after her husband’s diagnosis 
of penile TB.   An endometrial biopsy was 
obtained and revealed multiple caseating 
granulomas of an unknown cause.  She had no 
known previous infection with TB, but had been 
having unprotected sexual intercourse with her 
husband prior to his diagnosis.  Urine and 
abdominal ultrasound results were unremarkable, 
but an inactive calcified granuloma in the left 
apex of the lung was discovered.  A second 
biopsy of the endometrium was performed and 
culture produced M. tuberculosis.  Following this 
discovery, restriction fragment length 
polymorphism analysis was performed and 
confirmed that both husband and wife had been 
infected by identical organism, thus making this 
the first confirmed case of sexually transmitted 
TB. 
 
 
 
 
Presentation 
 
Clinically, TB of the penis generally presents 
either as superficial ulcers of the skin or glans of 
the penis, or as tuberculous cavernositis 
(inflammation of the cavernous bodies).4, In most 
cases, the lesion appears as a superficial ulcer on 
the glans or around the corona, as this is the most 
common part abraded during sexual contact or 
with infected clothing.2,7 The normal penile 
mucosa is highly resistant to tuberculosis, but in 
the case of sexual transmission, the bacilli are 
inoculated into abrasions caused by vigorous 
sexual activity.7 Although the glans and corona 
are most commonly affected, the lesions can also 
be extensive, with involvement of the urethra and 
corpus cavernosum, and rarely may even present 
as hardened nodules.2 Male patients with penile 
tuberculosis can present with impotence, and 
advanced cases may also present with erectile 
failure due to tuberculous caveronositis.3,7   
 
Female genitourinary tuberculosis is 
associated with infertility, although diagnosis is 
difficult since patients are usually asymptomatic. 
Some women (such as the one in the preceding 
case reports) do however present with symptoms 
such as menorrhagia, fever, sweats, weight loss, 
and malaise.   
 
Making the diagnosis 
 
The differential diagnosis of chronic penile ulcer 
with histological features of granulomas is 
extensive, and thus diagnosis of penile disease 
can often be difficult.3 Consideration needs to be 
given to bacterial and fungal infections (such as 
syphilis and herpes simplex), parasitic infections, 
vasculitides, inflammatory bowel disease, 
sarcoidosis, penile carcinoma, foreign body 
reactions, and other rare causes.3,5  
 
In general, the basic process used to 
diagnose TB of the penis includes physical 
examination revealing typical clinical features, 
positive Mantoux test, raised ESR, and the typical 
histopathological findings. More specifically, the 
presence of acid-fast bacilli in the smear 
examination, and typical granuloma with giant 
cells and caseous foci on histopathology with no 
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evidence of malignancy can help to clinch the 
diagnosis. Furthermore, chest X-ray, intravenous 
pyelography (IVP), urine culture and culture for 
Mycobacteria should be done to differentiate 
primary from secondary manifestations.9 
Intravenous urography should also be carried out 
to exclude upper renal tract TB.2 Clinical cure is 
possible through the treatment regimen described 
in the preceding case study, but relapses have 
been known to occur, making follow-up a 
necessity.  Patients diagnosed with penile TB 
should be counseled to abstain from sexual 
contact or at least use a condom for 4 to 6 weeks 
following treatment.8  
 
As with penile TB, the finding of 
caseating granulomas and Langerhans giant cells 
in association with chronic inflammation is 
diagnostic of endometrial TB. Though the 
tuberculin skin test does have some utility, it is 
not the most sensitive test available.  
Hysterosalpingograms (HSG’s) are very useful 
for visualizing the internal anatomy of the uterus, 
which may reveal features such as calcifications, 
occlusions, ‘beaded’ Fallopian tubes (if infected), 
and irregular uterine outlines if the patient does 
indeed have genitourinary TB.   However, even if 
a female patient is correctly diagnosed and 
effectively treated with antitubercular 
medications, the prognosis for future pregnancies 
remains poor.8 Thus, it is important to prevent the 
transmission of endometrial TB by all possible 
routes, including sexual transmission. 
 
Conclusions 
 
Although TB of the penis is rare, physicians need 
to be aware of this infectious disease when 
undiagnosed ulcers on the penis are observed. In 
particular, suspicion of cutaneous TB should be 
raised in countries which still show a high 
prevalence of tuberculosis, such as India where 
one third of the population is infected.2 Given that 
endometrial TB is associated with infertility, it 
should also be considered in female patients from 
TB endemic regions that have difficulty 
conceiving.  Since sexual transmission of TB is 
possible, as evidenced by the case reports in this 
article, it is also important to consider the 
implications for partners of infected patients 
engaging in unprotected sex.  Thus, awareness of 
the extrapulmonary manifestations of TB and 
proper counselling of patients with GU 
manifestations in particular is crucial in 
preventing the serious sexual and reproductive 
consequences of this disease. 
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Rabies is a viral neuroinvasive disease that causes encephalopathy in mammals.  Vaccination is the primary 
method of rabies prevention, given as both pre- and post-exposure prophylaxis.  North America is currently 
experiencing a heightened rabies threat due to recent problems in vaccine production.  Since 2007, the 
pharmaceutical industry has been struggling to meet North American demand for the rabies vaccine.  The 
Food and Drug Administration (FDA) and the two vaccine-producing pharmaceutical companies, Sanofi-
Pasteur and Novartis, are jointly responsible for the current supply shortage.  This shortage of rabies 
vaccine has resulted in a rationed approach to delivering prophylaxis.  Conservative measures such as 
avoidance behavior and vaccination of animals are to be used in place of pre-exposure prophylaxis.  Public 
health officials must review all cases in which post-exposure prophylaxis is requested to ensure the limited 
supply of vaccine is appropriately distributed. 
 
Introduction 
 
Rabies is a viral neuroinvasive disease that causes 
encephalopathy in mammals.  The most common 
vector for human infection is animal bites, and if 
untreated, rabies is almost always fatal.  While 
rabies has been well controlled or eradicated in 
some areas of the world, death from rabies is not 
uncommon in Asia and Africa.  Prevention of 
rabies by vaccination has been a mainstay of 
prophylaxis since the late 19th-century and is 
largely responsible for declining incidence in both 
animals and humans in North America.1  
 
North America is currently experiencing a 
heightened rabies threat due to recent problems in 
vaccine production.  Since 2007, the 
pharmaceutical industry has been experiencing 
problems in meeting North American demand for 
the rabies vaccine.  This has affected the front 
lines of medicine by causing a disturbance in the 
practice of rabies prophylaxis.2 Here we will 
discuss rabies and the rabies vaccine, the events 
that precipitated the current shortage in supply 
and how this production-related strain on 
resources has caused a reactionary change in the 
practice of medicine. 
 
 
Background and epidemiology 
 
Rabies is considered a zoonotic infectious 
disease.  This implies transmission to humans and 
animals occurs via other animals.  It is an RNA 
virus belonging to the family Rhabdoviridae and 
genus Lyssavirus and is contained in the saliva of 
infected mammals.1 After a bite occurs, the virus 
enters the central nervous system of the next host 
and causes non-specific prodromal symptoms 
followed by progressive encephalitis that is 
almost always fatal.  Early symptoms include 
paresthesias, pruritis and pain at the site of viral 
entry.  In humans the incubation period usually 
varies from several weeks to months. Diagnosing 
rabies is difficult due to the long and variable 
incubation time, as well as the lack of symptom 
specificity.2 
 
Historically, the most common vectors for 
rabies transmission have been domestic and stray 
dogs and cats.  In the United States in 1946 over 
8300 rabies cases were reported among dogs.  By 
2006, aggressive canine vaccination programs and 
improved stray animal control have resulted in a 
greater than ten-fold reduction in canine rabies 
cases.  This has translated into a roughly ten-fold 
drop in human rabies cases in the United States.3 
There has been an increasing rate of rabies in 
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traditionally forest-dwelling wildlife such as 
skunks, bats and raccoons.  This is concerning as 
urbanization and suburbanization increases in 
North America and these animals are in greater 
contact with humans.  Between 2000 and 2005, 
40% of Canada’s 2238 confirmed animal rabies 
cases were skunks, 26% were bats, and 8% were 
raccoons. Only two rabies deaths have been 
reported in Canada since 1985 and both were 
caused by bat exposure.4 Responding to changes 
in the pattern of rabies transmission requires 
adequate supply and effective use of preventive 
measures. 
 
The rabies vaccine and prophylaxis 
 
Prior to the development of the first rabies 
vaccine by Louis Pasteur and Emile Roux in 
1885, almost all rabies infections resulted in 
death.  This early vaccine was developed by 
harvesting cells from nerve tissue of infected 
rabbits.5   Research into an attenuated strain of the 
virus led to the development of new vaccines 
including the human diploid cell rabies vaccine in 
1967 and a newer, less expensive purified chick 
embryo vaccine.  These are available as Imovax® 
by Sanofi-Pasteur and RabAvert® by Novartis, 
respectively.  They are the only two rabies 
vaccines currently approved for use in Canada 
and the United States. 
 
In humans, rabies vaccines are intended 
for pre- and post-exposure prophylaxis.  Pre-
exposure prophylaxis is indicated for those at 
high risk of contacting the virus, such as 
veterinarians, animal trappers, and travelers to 
certain regions in Asia and Africa.  Post-exposure 
prophylaxis is given to those who have 
experienced open skin wounds as a result of an 
animal encounter.  Individuals that have never 
received the vaccine and are in need of post-
exposure prophylaxis also require rabies 
immunoglobulin to provide intermittent 
immunity.  Post-exposure prophylaxis with rabies 
vaccine in humans has been validated as an 
effective and safe method of preventing infection, 
particularly when administered within 6 days of 
exposure.1  Thus, the recent shortage in rabies 
vaccine supply to North America has been of 
great concern, particularly to those in immediate 
need of prophylactic treatment. 
 
Cause and implications of the vaccine shortage 
 
A current shortage of rabies vaccine has resulted 
in a rationed approach to delivering prophylaxis 
in North America.  Much like other elements of 
preventive medicine such as colonoscopies, the 
indications for receiving the rabies vaccine have 
become more stringent in response to strained 
resources.  Unique to the shortage of rabies 
vaccine is that the origin of the resource 
constraint is not intrinsic to the healthcare system; 
there are no infrastructure, human resource or 
financial constraints limiting the use of rabies 
vaccine.  The Food and Drug Administration 
(FDA) and the two vaccine-producing 
pharmaceutical companies, Sanofi-Pasteur and 
Novartis, are jointly responsible for the current 
supply shortage. 
 
In June 2007, Sanofi-Pasteur began 
renovating its Imovax® production facility in 
France in order to comply with new requirements 
from the FDA and a French regulatory body.  
Prior to these renovations the company stockpiled 
a finite amount of vaccine that was expected to 
meet demand until the facility re-opened.  Shortly 
after renovations began it became evident that the 
estimation of demand was incorrect and the 
stockpiled supply would be inadequate.6 Also at 
this time Novartis, which controls 50% of the 
North American rabies vaccine market, 
experienced FDA scrutiny and was asked to 
temporarily halt production of RabAvert®.  
Public health and industry officials have since 
declared that the rabies vaccine should be used for 
post-exposure prophylaxis only.  Conservative 
measures such as avoidance behavior and 
vaccination of animals are to be used in place of 
pre-exposure prophylaxis.  Public health officials 
must review all cases in which post-exposure 
prophylaxis is requested to ensure the limited 
supply of vaccine is appropriately distributed.  
RabAvert® was recently cleared by the FDA, and 
Novartis has been attempting to meet vaccine 
demand.  However, as of October 2008, the 
Center for Disease Control (CDC) has not 
changed recommendations for prophylaxis and 
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has informed travelers to certain regions in Asia 
and Africa that pre-travel vaccination is not 
available.6 Current projections estimate the supply 
of vaccine to restore to normal in mid-2009 upon 
the re-opening of the Imovax® production 
facility.6 
 
Discussion 
 
For many years the international pharmaceutical 
industry has acted alone and in conjunction with 
governments around the world to change the 
landscape of modern medicine.  Positive 
economic pressure, such as the encouragement of 
research and development by government 
incentives, has translated into economic growth 
for nations and an intended improvement of 
quality of life of the masses.  Stringent regulatory 
forces on the pharmaceutical industry have also 
had a trickle-down effect in which government 
bodies or other stressors temporarily shock the 
business of drug production, which in turn 
changes the way medicine is practiced.  This is 
evident in the recent shortage of rabies vaccine in 
North America.   
 
The practice of medicine in Canada has 
attempted to demonstrate flexibility and poise 
amidst a storm of stressors. Elements of 
healthcare delivery have crumbled in the face of 
limited resources while other areas have thrived 
on the heels of innovation.  For example, some 
Canadians have had to seek more timely care in 
the United States or overseas.  However, others 
have benefited from new models of primary care, 
allowing them to attain both timely and high 
quality care.  While these examples are 
considered to be largely intrinsic to our method of 
healthcare delivery, it is important to note that 
external forces may also drastically change the 
practice of medicine.   
 
The current philosophy of medicine in the 
Western World requires the efficient production 
of pharmaceutical agents as well as regulatory 
bodies to ensure the safety of the population.  The 
nature of the pharmaceutical industry makes it 
necessary for the practice of medicine is agile and 
prepared to deal with sudden change. 
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Introduction 
 
When one thinks of infectious disease, 
endocarditis – infection of the heart- does not 
always leap to mind.  However endocarditis is a 
serious life-threatening condition if not diagnosed 
and treated promptly.  Infective endocarditis is 
inflammation of the inner surface of the heart 
following microorganism colonization. This 
creates the prototypical lesion of infective 
endocarditis called the vegetation, a mass of 
platelets, fibrin and microorganisms.  Infective 
endocarditis results in damage and destruction of 
heart valves, specifically the aortic valve.  The 
purpose of this article is to provide a synopsis for 
medical students about the prevalence of infective 
endocarditis, the pathogenesis and microbes 
responsible for the disease and the signs and 
symptoms of infective endocarditis, with 
particular emphasis on diagnosis and treatment. 
 
Epidemiology and Pathogenesis 
 
Infective endocarditis is a relatively uncommon 
infectious disease, but failure to recognize it in 
predisposed patients can have disastrous 
consequences resulting in heart failure, embolism 
and even death.  It occurs with an incidence of 1.7 
to 7.0 episodes per 100 000 people in North 
America, and occurs in 1.4% of patients within 
the first year following  aortic valve 
replacement.2,3,4,5 Patients on dialysis infrequently 
develop endocarditis, but have high mortality.  
For a patient to develop endocarditis of the aortic 
valve, they typically have a cardiac abnormality 
leading to jet injury across the valve and they 
must have blood borne microbial colonization of 
the valve surface.1 Patients at particular risk for 
developing infective endocarditis may have a 
congenital heart abnormality, such as congenital 
bicuspid aortic valve, degenerative aortic stenosis, 
aortic calcification, rheumatic aortic valve disease 
or prosthetic heart valves.  Highly virulent 
microorganisms, such as Staphylococcus aureus, 
can cause endocarditis in people with normal 
aortic valves. 
 
The pathogenesis of aortic valve 
endocarditis occurs from a sequence of events 
which allow microorganisms to gain access to the 
valve and destroy it.  An initial insult to the valve 
occurs, independent of infection, damages the 
valve and allows microbes to colonize.  
Microorganism colonization may spread to the 
adjacent structures such as aortic annulus, mitral 
valve and aortic root and form an abscess.  It is 
possible for the abscess to rupture and spread into 
the pericardial cavity.  Infective endocarditis 
destroys the cusps of the aortic valve and can also 
lead to cardiac fistulas and paravalvular 
abscesses.  Thrombosis of microbial vegetations 
from the aortic valve can lead to coronary and 
systemic embolic events such as acute myocardial 
infarction,  cerebral aneurysms, strokes, or 
ischemic arterial occlusions.6 Organs at particular 
risk of infracting from vegetative embolisms are 
the spleen, the liver, the kidneys and limbs.29 The 
mitral valve can become secondarily involved if 
large vegetations from the aortic valve prolapse 
into the left ventricle and contact the leaflets of 
the mitral valve.7,8  
 
The infective organisms involved in aortic 
valve endocarditis depend on whether the valve is 
native or prosthetic.  Staphyloccous aureus and 
streptococcus viridans are the two most common 
bacteria responsible for infecting native heart 
valves.  S. aureus is very virulent and can cause 
infective endocarditis in people with no 
predisposing cardiac lesions.  S. viridans is not as 
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virulent and infects people with predisposing 
lesions, such as calcified aortic valves or 
congenital bicuspid valves.  Streptococcus 
epidermidis and other streptococci are also able to 
infect native heart valves.   
 
Endocarditis due to Gram negative 
bacteria is uncommon, but is very serious as these 
microbes tend to be antibiotic resistant.  These 
microbes include Hemophilus, Actinovacillus, 
Cardiobacterium, Eikenella and Kingella – the 
HACEK group of bacteria.  Endocarditis due to 
fungal infection predominantly involves Candida 
albicans and Aspergillus fumigatus and tends to 
be rare but extremely serious. 
 
Prosthetic valve endocarditis is defined as 
early onset if it occurs within two months after 
valve replacement and is considered late if it is 
more than two months after surgery.10 Prosthetic 
valve endocarditis can be due to colonization of 
the valve after the surgery or due to a 
contaminated valve being implanted, which may 
lead to endocarditis up to one year after surgery.10 
Early prosthetic valve endocarditis is due to 
contamination of the valve at the time of surgery.  
The microbes responsible are S. aureus, S. 
epidermidis and Enterococcus faecalis.5,11 The 
etiology of late prosthetic valve endocarditis is 
more difficult to determine, but it is most likely 
due to bacteremia and colonization of the 
prosthetic valve, usually by S. aureus or, S. 
epidermidis but can be caused by many other  
microbes.12,13,14 It is important to obtain blood 
cultures in endocarditis patients, so as the correct 
antibiotic can be used, however, there are cases of 
culture negative endocarditis where no 
microorganism is cultured from the valve tissue 
or from blood.11  
 
Diagnosis 
 
Clinically, endocarditis is classified as acute or 
subacute.  Subacute endocarditis is caused by less 
virulent organisms, such as S. viridans, and 
occurs in patients with a preexisting diseased or 
prosthetic aortic valve.  Patients present with low 
grade fever, malaise and symptoms suggestive of 
the flu.  Physicians tend to treat these patients 
with antibiotics which will improve symptoms 
within 10 days; however discontinuing the 
antibiotics may cause symptoms to return.  On 
physical exam, the patient’s only abnormal heart 
findings may be an aortic murmur.  Other 
physical findings include splenomegaly and 
petechia, a rash caused by hemorrhage of 
capillaries that can occur anywhere on the body.  
Patients with long standing congenital valve 
disease may also have evidence of clubbing.  
Patients can present with congestive heart failure 
(CHF) due to aortic insufficiency.  Vegetation 
thromboemoblism can also occur causing 
myocardial infarction, stoke, splenic or hepatic 
infarcts.  Blood cultures should be obtained, as 
well as complete blood cell count looking for 
leukocytosis or anemia which may indicate 
infection. 
 
Acute endocarditis is generally caused by 
more virulent organisms like S. aureus, and can 
affect people with normal aortic valves.  
Antibiotics alone will not be able to eradicate the 
infection.  Patients present with all the signs and 
symptoms of subacute endocarditis but have more 
severe symptoms and overwhelming sepsis.  
Signs unique to acute endocarditis include the 
Janeway lesion, a painless red-blue lesion found 
on the soles of feet and the palms of the hands, 
and the Roth spot, an oval pale area surrounded 
by hemorrhage in the optic disc.  Acute 
endocarditis patients may not necessarily have a 
history of pre-existing valve disease.  If the 
patients have a paravalvular abscess, they likely 
have abnormal EKG findings including prolonged 
PR interval or evidence of heart block. 
 
Doppler echocardiography is an extremely 
useful tool in diagnosing infective endocarditis.  It 
is able to detect vegetations as small as 1-2 mm in 
size and is very sensitive in detecting paravalvular 
abscess and cardiac fistulas.  In general, 
transesophgeal echocardiography (TEE) with 
multiplane views is much more sensitive than 
transthoracic echocardiography (TTE)14,15  
 
Physicians from Duke University 
recommended criteria for the diagnosis of 
infective endocarditis, which has been modified 
over the years in attempts to improve its 
limitations.16 In general, there are major and 
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minor criteria which are suggestive of 
endocarditis.  A patient is said to definitively have 
endocarditis if they have two of the major criteria, 
or 1 major criterion and 3 minor criteria, or 5 
minor criteria.  A patient is said to possibly have 
endocarditis if they have 1 major criterion and 
one minor criterion or if they have 3 minor 
criteria (Table 1). 
 
Treatment 
 
The first line treatment of infective endocarditis is 
use of antibiotics.  The choice of antibiotic 
depends on the clinical circumstances and should 
begin after obtaining blood cultures.  Patients 
with recent dental work should be given 
antibiotics against bacteria of the oral cavity.  
Patients with a recent urinary or colonic 
procedure should be given antibiotics against 
Gram negative bacteria.  IV drug users are at risk 
of S. aureus and S. epidermidis, and antibiotic 
therapy should be directed against these bugs.  
The use of 2 or 3 antibiotics that will increase the 
effect of each other is the best treatment for 
endocarditis caused by virulent organisms, and 
should be administered intravenously for 6 weeks.  
It often proves difficult to treat endocarditis with 
just antibiotics, especially when dealing with 
virulent organisms, like S. aureus, Pseudomonas 
aeruginosa, Serratia marescens or fungus 
endocarditis.  These organisms destroy the native 
aortic valve leading to aortic insufficiency and 
congestive heart failure (CHF). 
 
Once antibiotic therapy has been started, 
surveillance blood cultures should be taken within 
48 hours to monitor the efficacy of the treatment.  
The patient should be monitored for signs of 
CHF, thromboembolism and infection.  In the two 
weeks following diagnosis, the patient should 
have daily electrocardiogram (EKG) and frequent 
echocardiogram.  Abnormal findings of aortic 
abscesses or large vegetative growths should 
prompt immediate surgical intervention to prevent 
heart failure, shock or embolism.14,17,18 
Anticoagulation therapy isn’t recommended in 
patients with endocarditis.  It does not prevent 
embolization of vegetations and it is associated 
with an increased risk of neurological 
complications.19  
 
Patients with endocarditis who develop 
CHF, acute valve dysfunction, paravalvular 
abscess, cardiac fistula, sepsis or embolization of 
vegetations despite adequate antibiotic therapy 
should receive surgical intervention.  Patients 
with prosthetic valve endocarditis, especially 
mechanical valves, who are infected with S. 
aureus have better outcomes with early 
surgery.9,13 
 
Table 1 - Modified Duke criteria for diagnosis of infective endocarditis.16 
Definite infective endocarditis 
Pathologic criteria 
(1) Microorganisms demonstrated by culture or histologic examination of a vegetation, a vegetation that has 
embolized, or an intracardiac abscess specimen; or 
(2) Pathologic lesions; vegetation or intracardiac abscess confirmed by histologic examination showing 
active endocarditis 
Clinical criteria 
(1) 2 major criteria; or 
(2) 1 major criterion and 3 minor criteria; or 
(3) 5 minor criteria 
Possible infective endocarditis 
(1) 1 major criterion and 1 minor criterion; or 
(2) 3 minor criteria 
Rejected 
(1) Firm alternate diagnosis explaining evidence of infective endocarditis; or 
(2) Resolution of infective endocarditis syndrome with antibiotic therapy for 4 days; or 
(3) No pathologic evidence of infective endocarditis at surgery or autopsy, with antibiotic therapy for 4 days; or 
(4) Does not meet criteria for possible infective endocarditis, as above 
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Patients undergoing urgent heart surgery 
for endocarditis often have poor heart function 
and the surgical procedure is both lengthy and 
complex.  In patients with infection limited to the 
cusps of the aortic valve, the native valve should 
be removed and replaced with a prosthesis.  There 
is no evidence whether mechanical or 
bioprosthetic valves are superior in endocarditis 
patients, and treatment will ultimately depend on 
the preference of the surgeon and the patient.23 In 
young patients, some surgeons prefer the use of 
pulmonary autografts.24   
 
Involvement of the aortic annulus, 
whether necrosis or inflammation, needs to be 
surgically resected before implanting a prosthetic 
valve and patched over with autologous 
pericardium or glutaraldehyde fixed bovine 
pericardium.25,26 In extensive destruction of the 
aortic root, all infected tissues should be resected 
and replaced with a pulmonary autograft.27 The 
effects of infection associated with endocarditis 
are unpredictable, and as such different parts of 
the heart will need to be resected, repaired or 
replaced depending on the degree of damage. 
 
Postoperatively, patients should be 
observed closely.  Sepsis, coagulopathy and 
hemorrhage are common postoperative 
complications.  Coagulopathy and bleeding 
should be treated with antifibrinolytic agents, 
fresh frozen plasma, platelets, and cryoprecipitate 
as needed.  Resection of an aortic root abscess can 
lead to heart block and patients may require 
implantation of pacemakers.  Further surgical 
treatment may be required for metastatic 
abscesses and vegetative embolisms to other 
organs, requiring collaboration with other surgical 
specialties. 
 
Conclusion 
 
Infective endocarditis is a serious infection, 
leading to destruction of the aortic valve and 
resulting in a host of symptoms.  Prompt 
diagnosis can be made by careful history, 
echocardiography and blood cultures. Effective 
antibiotic therapy with a minimum duration of 6 
weeks is the mainstay of treatments; surgical 
interventions are reserved for those with un-
controllable sepsis, structure-related heart failure, 
abscess formation, large vegetations and 
prosthetic valve endocarditis. 
 
References 
 
1. Lamas CC, Eykyn SJ. Bicuspid aortic valve – a 
silent danger: analysis of 50 cases of infective 
endocarditis. Clin Infect Dis 2000: 30:336-41. 
2. King JW, Nguyen VQ, Conrad SA. Results of a 
prospective statewide reporting system for 
infective endocarditis.  Am J Med Sci 1988; 
295:517-27. 
3. Berlin JA, Abrutyn E, Strom BL, et al. Incidence 
of infective endocarditis in the Delaware Valley, 
1988-1990. Am J Cardiol 1995; 76:933-6. 
4. Tleyjeh IM, Steckelber JM, Murad HS, et al. 
Temporal trends in infective endocarditis: a 
population-based study in Olmsted County, 
Minnesota. JAMA 2005; 293:3922-8. 
5. Gordon SM, Serkey JM, Longworth DR, et al. 
Early onset prosthetic valve endocarditis: the 
Cleveland Clinic experience 1992-1997. Ann 
Thorac Surg 2000; 69:1388-92. 
6. Mylonakis E, Calderwood SB. Infective 
Endocarditis in adults. N Engl J Med 2001; 
345:1318-30. 
7. Piper C, Hetzer R, Korfer R, et al. The 
importance of secondary mitral valve 
involvement in primary aortic valve endocarditis: 
the mitral kissing vegetation. Heart 2002; 23:79-
86. 
8. Gillinov AM, Diaz R, Blackstone EH, et al. 
Double valve endocarditis. Ann Thorac Surg 
2001; 71:1874. 
9. D’Udekem Y, David TE, Feindel CM, et al. 
Long-term results of surgery for active infective 
endocarditis. Eur J Cardiothorac Surg 1997; 
11:46-52. 
10. Calderwood SB, Swinsk LA, Waternaux CM, et 
al. Risk factors for development of prosthetic 
valve endocarditis. Circulation 1985; 72:31-7. 
11. Fang G, Keys TF, Gentry LO, et al. Prosthetic 
valve endocarditis resulting from nosocomial 
bacteremia: a prospective, multicenter study. Ann 
Intern Med 1993; 119:560-7. 
12. David TE. The surgical treatment of patients with 
prosthetic valve endocarditis. Semin Thorac 
Cardiovasc Surg 1995; 7:47-53. 
13. Watanakunakorn C, Burket T. Infective 
Endocarditis at a large community teaching 
hospital, 1980-1990: a review of 210 episodes. 
Medicine 1993; 72:90-102. 
 
UWO Medical Journal, Vol 78, Issue 2    Page | 57 
14. Buda AJ, Zotx RJ, Lemire MS, Back DS. 
Prognostic significance of vegetations detected 
by two-dimensional echocardiography in 
infective endocarditis. Am Heart J 1986; 
112:1291-6. 
15. Daniel WG, Mugge A, Martin RP, et al. 
Improvement in diagnosis of abscess associated 
with endocarditis by transesophgeal 
echocardiography. N Engl J Med 1991; 324:795-
800. 
16. Li JS, Secton DJ, Mick N, et al. Proposed 
modifications to the Duke Criteria for the 
diagnosis of infective endocarditis. Clin Infect 
Dis 2000; 30:633-8. 
17. Lowry RW, Zoghbi WA, Baker WB, et al. 
Clinical impact of transesophageal 
echocardiography in the diagnosis and 
management of infective endocarditis. Am J 
Cardiol 1994; 73:1089-91. 
18. DiSalvo G, Habib G, Pergola V, et al. 
Echocardiography predicts embolic events in 
infective endocarditis. J Am Coll Cardiol 2001; 
15:1069-76. 
19. Ting W, Silverman N, Levistky S. Valve 
replacement in patients with endocarditis and 
cerebral septic emboli. Ann Thorac Surg 1991; 
51:18. 
20. Sett SS, Hudon MPJ, Jamieson WRE, et al. 
Prosthetic valve endocarditis: experience with 
porcine bioprostheses. J Thorac Cardiovasc Surg 
1993; 105:428-34. 
21. Larbalestier RJ, Kinchla NM, Aranki SF, et al. 
Acute bacterial endocarditis: optimizing surgical 
results. Circulation 1992; 86(Suppl II):68-74. 
22. Alexiou C, Langley SM, Stafford H, et al. 
Surgery for active culture-positive endocarditis: 
determinants of early and late outcome. Ann 
Thorac Surg 2000; 60:1448-54. 
23. Moon MR, Miller DC, Moore KA, et al. 
Treatment of endocarditis with valve 
replacement: the question of tissue versus 
mechanical prosthesis. Ann Thorac Surg 2001; 
71:1164-71. 
24. Oswalt JD, Dewan SJ, Mueller MC, et al. 
Highlights of a ten-year experience with the Ross 
procedure.  Ann Thorac Surg 2001; 71:S332-5. 
25. David TE, Komeda M, Brofman PR: Surgical 
treatment of aortic root abscess.  Circulation 
1989; 80(Suppl 1):269-74. 
26. D’Udekem Y, David TE, Feindel CM, et al. 
Long-term results of operation for paravalvular 
abscess.  Ann Thorac Surg 1996; 62:48-53. 
27. Pettersson G, Tingleff J, Joyce FS. Treatment of 
aortic valve endocarditis with the Ross procedure.  
Eur J Cardiothorac Surg 1998; 13:678-84. 
28. David TE, Kuo J, Armstrong . Aortic and mitral 
valve replacement with reconstruction of the 
intervalvular fibrous body.  J Thorac Cardiovasc 
Surg 1997; 114:766-71. 
29. Durack DT, Beeson PB, Petersdorf RG. 
Experimental bacterial endocarditis, III: 
producton and progress of the disease in rabbits.  
Br J Exp Pathol 1973; 54:142-51. 
 
Page | 58 
FEATURE 
Infection with H5N1 virus: presentation and vaccine development 
 
Hamid Mithoowani (Meds 2012) and Nihal Haque (Meds 2012) 
Faculty Reviewer: Dr. Zafar Hussein 
 
Introduction to influenza A (H5N1) 
 
Avian flu, or Influenza A (H5N1), is an RNA 
virus belonging to Influenzavirus A, one of the 
five genera classified under the Orthomyxoviridae 
family. Influenzavirus A has only one species, 
Influenza A, which has been responsible for all 
worldwide influenza pandemics.1 These viruses 
are further subdivided according to two important 
surface protein antigens, hemagglutinin and 
neuraminidase. Variations within these proteins 
have been responsible in pandemic strains of 
influenza such as the Spanish Flu (H1N1), which 
claimed upwards of 20 million lives.2 Human 
cases of Avian flu primarily belong to the H5N1 
subtype, though rarer subtypes others have been 
noted.1 The presentation and vaccine development 
of the H5N1 subtype is contrasted to H1N1, but 
the same applies for H3N2, the other major 
subtype of human influenza virus. 
 
H5N1 human infection was discovered in 
1997 and subsequently re-emerged in 2003-2004 
in poultry and human populations in several 
Asian countries.1 Patients present with symptoms 
2-4 days after exposure but may be asymptomatic 
for up to 8 days.1, 2 Unlike seasonal influenza, the 
nature of virus shedding in these cases is 
unknown at this point. Besides the common 
symptoms of cough, fever and shortness of 
breath, there are several features unique to 
infection with H5N1. Unilateral pneumonia 
progressing into a bilateral pattern within the span 
of 4 days is more common and can be detected on 
an X-ray. This is different from the cases of 
pneumonia which develop subsequent to H1N1 
infection as they are quite rare. The mortality of 
patients infected with H5N1 approaches 60% and 
death occurs due to respiratory failure secondary 
to fulminant bilateral pneumonia.2 It should be 
noted that this rate has been obtained from 
reported cases and that the actual number might 
be higher. As opposed to H1N1, H5N1 might 
involve extrapulmonary sites as well. For 
example, viral RNA has been isolated from the 
blood of patients who died from H5N1 infection.3 
Furthermore, viral RNA has also been detected in 
areas such as the liver, lymph nodes and brain.4 
This may explain why H5N1 infection also 
produces gastrointestinal symptoms such as 
diarrhea, vomiting and abdominal pain. 
  
In the event of an outbreak of H5N1 
infection, the modes of transmission of the virus 
must be examined in order to initiate effective 
countermeasures. The H5N1 virus is present in 
poultry and most cases of human infection have 
occurred in situations where there is close contact 
with live or dead birds.3 There is also the 
possibility that infection occurs via the 
gastrointestinal tract as viral RNA has been found 
in feces of infected individuals.6 Finally, there 
have been very few cases of human-to-human 
spread at present and these cases involved lengthy 
contact with infected individuals.7 In summary, 
both animal-to-human and human-to-human 
spread remains inefficient at present but this 
could change if a mutation occurs in the H5N1 
virus. 
 
Vaccine development 
 
The World Health Organization monitors 
influenza activity throughout the world and makes 
a recommendation for the seasonal influenza 
vaccine every year.8 Postinfection ferret sera are 
tested in an assay called the hemagluttination-
inhibition (HI) test where hemagluttinin from 
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different strains of H1N1 are tested to see which 
elicits the highest immune response. This data is 
used to make a recommendation around February 
for the upcoming influenza season.  
 
An ideal vaccine for H5N1 infection 
should induce a strong mucosal antibody (IgA) 
response as the primary site of H5N1 infection is 
the respiratory tract.9 Due to the extrapulmonary 
nature of H5N1 infection, a vaccine which 
induces a cell-mediated response as well would 
help protect from systemic manifestations of 
infection. This cell-mediated response needs to be 
generated against conserved elements of the virus 
such as matrix and nucleoproteins as other 
components mutate rapidly. Finally, this vaccine 
should be easy to produce as large amounts will 
be needed in the event of a potential or imminent 
pandemic. 
 
Inactivated H1N1 influenza viruses are 
used for prophylaxis against seasonal influenza.9 
This approach is restricted to a  humoral immune 
response only. Live attenuated H1N1 viruses 
were developed to overcome this hurdle as they 
induce cell-mediated responses as well. These 
approaches are not helpful for H5N1 human 
infection because of the long period of time 
required to produce these vaccines due to the 
requirement of chicken eggs to complete the 
process. Another problem with using live 
attenuated viruses for H5N1 infection prophylaxis 
is that there is the chance of developing a deadlier 
strain if they undergo genetic reassortment with 
another strain. Live attenuated H5N1 viruses have 
been shown to induce immunity in chickens when 
challenged to H5N1 infection however and will 
most likely be used as a last resort during a 
pandemic. 10 
 
The use of adenoviruses as vectors 
provides an attractive alternative to develop 
vaccines for H5N1 human infection.11 
Specifically, adenovirus serotype 5 can be 
genetically engineered to express hemagluttinin 
specific to H5N1. The production of adenovirus 
vectors is faster than that used for influenza 
vaccines since they do not require the use of 
chicken eggs. These vaccines can be administered 
intranasally and this eliminates the need for 
specialized personnel to administer them in the 
event of a pandemic. The main drawback to this 
modality is that a certain segment of the world 
population is immune to this subtype of 
adenovirus and this may dampen the response to 
hemagluttinin required as the virus may be 
cleared quickly. However, it has been shown that 
even in people who possess natural immunity, the 
vaccine induces antibody production against 
hemagluttinin.11 Once large-scale studies 
examining the safety profile and efficacy of 
adenovirus-vectored vaccines is complete, they 
can be produced in large quantities to be used as 
prophylaxis during a pandemic. 
 
The role of influenza A (H5N1) vaccines in a 
global pandemic 
 
A potential H5N1 pandemic can be a serious 
threat to global health. Applying data from the 
1918 flu pandemic, a computer model has been 
developed that predicts between 50 and 80 
million people worldwide could be victims to 
H5N1.12  Preventing a pandemic of this 
magnitude requires controlling it and containing it 
as early as possible. Vaccines play an important 
role in controlling H5N1, and the World Health 
Organization (WHO) has announced that they 
will be stockpiling vaccine in preparation for a 
global pandemic.13 The current plan put forth by 
the WHO is to stockpile 50 million vaccines, 
which would protect 25 million people at two 
doses per person.14 The WHO is charting new 
territories with regards to stockpiling vaccines. 
Usually, vaccines for pandemics cannot be 
prepared until the particular strain of virus makes 
its way into the population. Using current vaccine 
development technology, this could take at least 
4-6 months after the WHO declares a particular 
strain of virus to be a pandemic.15  The current 
strategy is to stockpile “prepandemic” vaccines. 
This involves preparing vaccines with currently 
circulating H5N1 strains, but with cross-reactivity 
to other emerging strains. For the development of 
an effective vaccine, it is essential to monitor 
H5N1 strains as well as any drift which occurs by 
the accumulation of mutations in H and N 
antigens. This would require rapid testing of 
patients at the level of individual communities. 
Cultures should be obtained from patients in 
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designated clinics which are representative of the 
community.16 This information should then be 
escalated to a local public health office. Patients 
receiving the vaccine would be primed towards 
H5N1, buying time until a more specific booster 
is developed and administered.17 To adapt to other 
strains, cross-reactivity is elicited by adding 
certain adjuvants to the vaccine, which also 
induce a stronger immune response and require 
lower doses of vaccine to be administered. 
GlaxoSmithKline is developing an inactivated, 
prepandemic vaccine for H5N1 which has 
undergone phase I and II clinical trials, and has 
been found to be safe in healthy adult 
volunteers.18  
  
There are logistical issues surrounding 
stockpiling not limited to distributing of millions 
of vaccines and making vaccines available to the 
developing world. It is a global responsibility to 
ensure that the developing world receive vaccines 
and will require global cooperation. The WHO 
has not come up with a specific plan regarding the 
stockpile use, and admit to still working on one. 
Another issue is the lack of data regarding 
vaccine safety and efficacy in large human 
clinical trials. There is little research on the 
vaccine in paediatric and elderly populations, 
which are considered to be at the highest risk for 
H5N1. Careful thought and planning must go into 
making decisions not only at the level of the 
laboratory, but in policy to ensure that stockpiling 
vaccines can be taken seriously as a solution to 
prevent a worldwide H5N1 pandemic. 
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Many people are affected by homelessness worldwide, in Canada and the U.S. Homelessness is associated 
with an increased risk of health problems due to overcrowding in shelters and host factors such as substance 
abuse, HIV co-infection, poor nutrition and hygiene, mental illness and trauma. Respiratory infections are 
among the most common problems that the homeless may present with and are associated with high 
morbidity and mortality. Certain respiratory infections are more common among homeless individuals and 
may be associated with complications unique to this population. Most of the literature in the field focuses 
on tuberculosis in the homeless or on specific outbreaks of respiratory infections. This article discusses the 
prevalence, risk factors, complications, treatment and prevention of tuberculous and non-tuberculous 
respiratory infections such as influenza and pneumonia caused by S pneumoniae, S aureus, H influenzae b, 
and anaerobes. 
 
Introduction 
 
Homelessness is an alarming social problem that 
affects up to 100 million people worldwide.1 The 
2001 Canadian census counted 14,145 individuals 
living in shelters, however, this largely 
underestimates the number as many homeless 
may not stay in shelters.2 Homelessness is also a 
significant health problem. Crowded shelters are 
favorable environments for infection and host 
factors such as poor nutrition, obesity, sedentary 
lifestyle, poor hygiene, alcoholism, drug use, 
smoking, mental illness, abuse, trauma, or HIV 
co-infection increase susceptibility to illness and 
may diminish immune systems.3,4,5,6 These 
factors, combined with decreased financial and 
personal resources, make the seeking out of 
medical help and compliance with treatment less 
likely. As a result, homeless people are more 
likely to suffer from respiratory infections, skin 
and foot infections, hepatitis, HIV, STI’s, and 
chronic disease.5  
 
Respiratory infections are among the most 
common medical issue that homeless individuals 
seek help for and shelters can be sources of 
outbreaks of tuberculosis and pneumonia.7 
Respiratory infections account for 33-42% of 
presenting complaints and 20% of total deaths in 
the homeless.3,8,9 The mortality due to respiratory 
illness is about seven times greater than expected 
in the homeless.9,10 This is compounded by the 
increased rate of chronic respiratory illness such 
as bronchitis (11.4%), asthma (8.6%) and COPD 
(5%). Several factors specifically predispose this 
population to respiratory infections including 
crowding, increased exposure to pathogens, 
smoking, alcohol and drug abuse, HIV 
seropositivity and chronic lung disease.3,6,9 This 
article will examine both tuberculous and non-
tuberculous respiratory infections such as 
pneumonia and influenza in the homeless as they 
are not only more common but are associated 
with greater morbidity, mortality and 
complications. 
 
Tuberculosis 
 
Tuberculosis is the most common respiratory 
infection among the homeless that is discussed in 
the literature. The estimated annual pulmonary 
TB rate for Canada and the U.S. is 2 per 
100,000.11 The urban homeless comprise a 
disproportionate burden of tuberculosis. The 
prevalence of active tuberculosis among the 
homeless in the U.S. is 1.6% to 6.8% and 18% to 
51% for latent disease.8 
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As with other respiratory infections, 
poverty, malnutrition and overcrowding are all 
risk factors for tuberculosis. Larger, more 
crowded shelters with increased people sharing 
the same breathing space increases transmission 
and poor ventilation or recirculation of air 
compounds this risk.8 HIV co-infection and 
alcoholism commonly complicate the course of 
infection. HIV is the single-most important risk 
factor for latent disease progressing to active 
disease and it is recommended that all individuals 
with TB be tested for HIV.5,8 Some studies link 
multi-drug resistance to homelessness, although 
contradictory data disputes this.5,12 Homelessness 
is associated with poor adherence, loss to follow-
up  and is an independent risk factor for no 
contacts.12,13 Contact tracing is accomplished by 
mass screening in shelters as opposed to 
searching for named contacts.3 
 
Screening and detection in the homeless is 
important for preventing TB resurgence.14 The 
CDC recommends that the detection of 
tuberculosis be given first priority as opposed to 
screening asymptomatic individuals.8 City-wide 
symptom screening programs have been 
implemented in Philadelphia shelters on intake to 
ensure that symptoms such as prolonged cough, 
night sweats, fever, and weight loss are further 
investigated.15  Mass screening in shelters has also 
been widely used with resulting decreases in 
tuberculosis transmission. No consensus has been 
reached about the most effective screening tool.1 
Tuberculin skin testing (TST) is likely the 
simplest and least expensive to administer, but 
lacks specificity and results in many false 
negatives in the immunocompromised.1,16 
Mandatory skin test screening in one U.S. study 
resulted in a decreased incidence of TB from 510 
to 121 cases per 100,000 per year.1 Spot sputum 
is also a fairly rapid screening technique but 50% 
of smears are negative and subsequent tracing of 
patients is difficult.1,8 Studies in incarcerated 
individuals show that chest radiography is likely 
to be the most cost-effective method. Annual 
snapshot screening for tuberculosis in shelters 
using combinations of these methods has been 
undertaken in Los Angeles and Marseille with 
great effectiveness.1 Certain shelters, as in 
Barcelona, imposed mandatory screening with 
chest radiography, TST and sputum culture upon 
shelter admission before access to free meal 
services.17  
 
Lack of treatment compliance is a 
common problem among the homeless. A 48% 
non-compliance rate was reported in New York in 
1991 leading to increased length of treatment 
(560 versus 324 days) and decreased completion 
of treatment. Directly observed therapy (DOT) 
and supervised housing programs are both 
effective methods used to increase 
compliance.5,8,18 Other novel solutions include 
financial or food incentives, transportation 
assistance and education using a peer health 
advisor.5,8,19 More dramatically, incarceration has 
also been evaluated as a method for treating 
patients refusing treatment.8,20 
 
Pneumonia 
 
Pneumonia affects over 1 million Americans 
annually and is the 6th leading cause of death with 
a 14% mortality rate among hospitalized 
patients.21 This burden is disproportionally shared 
by the homeless. An Edmonton-based study from 
2000-2002 showed a pneumococcal infection rate 
among the homeless of 266.7 per 100,000 
contrasted with 9.7 per 100,000 in the general 
population. Outbreaks of pneumococcal 
pneumonia more commonly occur in crowded 
shelters with high pneumococcal carriage rates of 
up to 60%. Shelter outbreaks in Chicago, Boston, 
Paris and the UK as well as in several provinces 
of Western Canada have been described in the 
literature. 20,22  
 
In addition to homelessness, risk factors 
for pneumonia include smoking, drug or alcohol 
use, HIV, asthma and COPD; all frequent 
comorbidities in the homeless. It is estimated that 
78% of homeless individuals are smokers and 
60% abuse alcohol.3,9,22,23 In two shelter 
outbreaks in Boston and Paris, the majority of 
those infected were alcoholics, smokers or had 
chronic bronchitis.9,24 Outbreaks of Hib 
pneumonia are also mostly found among 
alcoholic homeless patients.3,9 
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The most common organisms responsible 
for community acquired pneumonia in the 
homeless are Streptococcus pneumoniae, 
Staphylococcus aureus, and H influenzae b. 
Aspiration pneumonia is also frequent and 
organisms include anaerobes like 
peptostreptococcus, Fusobacterium nucleatum, 
Prevotella and bacteroides species. Pneumocystis 
carinii can be found in HIV positive 
individuals.20,21,22   
 
Vaccination against pneumococcal 
pneumonia is one method of reducing invasive 
pneumococcal disease in shelters.25 The Canadian 
National Advisory Committee on Immunization 
(NACI) recommends the use of 23-valent 
pneumococcal polysaccharide vaccine (PPV-23) 
in the homeless, those who use illicit drugs, HIV 
infected individuals and those with other chronic 
conditions such as COPD that are 
disproportionately higher in the homeless. 
Vaccination of hard to reach populations like the 
homeless can be challenging and a 1999 
vaccination campaign in Edmonton addressed this 
issue by targeting as many sites as possible 
including single room occupancy hotels, soup 
kitchens, community agencies, needle exchanges, 
pubs, parks and alleys. The year following the 
campaign, there was a decrease in the amount of 
emergency department visits for pneumonia (863 
compared to 646), and a decrease in admissions 
for pneumonia.22 Vaccination is also the best way 
to prevent Hib pneumonia in at-risk persons who 
are not immune.23 
 
Special considerations for pneumonia in 
the homeless include keeping a high index of 
suspicion for aspiration in those who abuse drugs 
and alcohol. One must also consider the difficulty 
of completing antibiotic regimens especially those 
with frequent dosing. Furthermore, there is often 
no safe storage for medications or a place to 
convalesce with closures of shelters during the 
day. Hospitalization or admission in a medical 
respite unit is worthwhile to ensure proper 
treatment.21 Smoking cessation is another 
important arm of prevention although it is often 
overlooked in the homeless due to falsely 
assumed lack of motivation.6 
 
Influenza 
 
Influenza affects millions of Americans per year 
and results in 100,000 hospitalizations and 36,000 
deaths annually. Influenza can result in secondary 
pneumonia and exacerbations of COPD or 
asthma.26 Despite the large morbidity and 
mortality associated with the virus, influenza 
among the homeless is very poorly studied. A 
New York-based study of 3 shelters evaluated 
4,319 charts for influenza-like illness with 59 
recorded cases, less than one fourth of which had 
been vaccinated. Vaccination against influenza 
has been advocated for in those at increased risk 
of influenza and pneumonia including the 
homeless, HIV-infected and those with COPD.27 
Influenza vaccination remains underutilized and 
organized efforts concentrated over a day or week 
to vaccinate all shelter residents and staff is 
suggested.26 Various strategies for improving 
vaccination rates include educational campaigns, 
improving patient-provider interactions, 
broadening the provider base, adoption of 
standing orders for immunization administration, 
and promoting wider availability and access to 
vaccine at the structural level.28 
 
Conclusion 
 
Homeless individuals are at increased risk of 
respiratory infections such as tuberculosis, 
influenza and pneumonia due to S pneumoniae, S 
aureus, H influenzae b and anaerobes.  Risk 
factors include overcrowding, increased pathogen 
exposure and host factors such as alcoholism, 
smoking, drug abuse, HIV co-infection and 
chronic lung disease. Morbidity, mortality and 
complications are greater in these specific 
populations and outbreaks are common. 
Diagnosis and treatment non-compliance are 
serious challenges. It is important to remember 
that respiratory infections and their complications 
in the homeless are largely influenced by social 
factors. Mindfulness of the unique risks and 
challenges associated with this population is 
important. It is only through comprehensive 
programs that involve initiatives like screening, 
immunization, low threshold for hospitalization, 
smoking cessation, and incentives or education to 
increase compliance, that effective prevention and 
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treatment of respiratory infections in the homeless 
can be attained. 
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The differential diagnosis of a neck mass can be extensive. In this short publication we will focus on an 
unusual neck mass whose features suggested that of extrapulmonary tuberculosis (TB). Though TB is 
endemic is some developing parts of the world, its rates of infection have drastically decreased in 
developed countries and the prevalence has remained relatively low. However with the emergence of AIDS 
and multi-drug resistant tuberculosis, we have seen a resurgence of TB infections. Though pulmonary TB is 
by far the most common presentation of tuberculosis, several extrapulmonary manifestations can present 
clinically. The presentation of interest that will be discussed in this article is Scrofula – the involvement of 
TB in the lymphatic system of the neck. 
 
A 45-year-old man of Indian ethnicity presented 
to the General Surgery Outpatient Clinic 
complaining of a left-sided, palpable, non-tender 
mass above the clavicle. The swelling had 
developed over a period of several weeks and had 
been progressively increasing in size. He was 
concerned about malignancy. There was no 
history of recent viral infections, fever, chills, 
weight loss, sweats, or any other systemic 
symptoms. He was otherwise healthy, active and 
worked at a marketing firm. The patient's past 
medical and surgical history was unremarkable. 
He lived alone in an apartment and had no pets. 
Two years previously he visited India for one 
week. The patient did not appear sick and was in 
no discomfort. His oral temperature was 36.7oC, 
pulse 70bpm with a blood pressure of 
140/70mmHg. A left-sided slightly indurated, 
non-tender 5cm supraclavicular mass was present 
just lateral to the sternocleidomastoid muscle. The 
overlying skin was slightly erythematous but 
there was minimal tenderness.  The oral cavity, 
face and scalp were normal. There was no 
enlargement of axillary or inguinal nodes and no 
hepatosplenomegaly. 
 
The white blood cell (WBC) count was 
normal and the erythrocyte sedimentation rate 
(ESR) and C-reactive protein were mildly 
elevated. An urgent contrast-enhanced computed 
tomography (CT) scan of the neck and chest 
showed a 2.8 cm x 5.3 cm well delineated soft 
tissue mass with a central area of lower 
attenuation. It was interpreted as a necrotic lymph 
node and lymphoma, metastatic cancer and 
infection were listed in the differential diagnosis. 
There was no mediastinal adenopathy and no 
pulmonary nodules. Four days after the initial 
consultation the mass was larger and fluctuant. 
Using local anaesthesia it was incised and thick 
pus without any odour was drained. Gram stain of 
the pus showed no organisms and routine 
anaerobic and aerobic cultures were negative. 
Stain for Acid Fast bacilli was negative and the 
culture for TB are still pending. When seen three 
weeks after the drainage, mass had resolved and 
the site of the incision was almost closed.  
 
Because of the patients presentation with a 
“cold abscess” (lack of locally marked findings of 
redness and tenderness and absence of systemic 
findings of inflammation), scrofula was 
entertained in the initial differential diagnosis. 
Scrofula is the term for tuberculous cervical 
lymphadenitis. Its origin is the latin word 
meaning “brood sow”. Scrofula has been known 
to afflict people since antiquity. In the middle 
ages it was believed that the royal touch of the 
king could cure the disease, hence it was known 
as the King's Evil. Kings were thought to have 
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received this power due to their descent from 
Edward the Confessor. Elaborate healing rituals 
were performed by monarchs to heal the afflicted 
of this disease. In 1768, the Englishman John 
Morley produced a handbook "Essay on the 
nature and cure of scrophulous disorders” which 
first described the typical symptoms and 
prognostic factors.1 Epidemiologically, 95% of 
the scrofula cases in adults, and 8% of cases in 
children, are caused by Mycobacterium 
tuberculosis. The rest are caused by atypical 
mycobacterium or nontuberculous 
mycobacterium (NTM). With the vast decrease of 
tuberculosis in the second half of the 20th 
century, scrofula became a very rare disease, 
however with the appearance AIDS it has shown 
a resurgence, and presently affects about 5% of 
severely immunocompromised patients. TB is 
responsible for up to 43 percent of all of 
peripheral lymphadenopathy in the developing 
world. Tuberculous lymphadenitis occurs in more 
than 4 children per 1000.2 
 
The most usual signs and symptoms are 
the appearance of a chronic, painless mass in the 
neck, which is persistent and progressive. The 
mass is referred to as a "cold abscess", because 
there are minimal findings of acute inflammation 
accompanying local and the overlying skin 
acquires a violaceous color. Scrofula caused by 
Mycobacterium tuberculosis is usually 
accompanied by other symptoms of the disease, 
such as fever, chills, malaise and weight loss in 
about 43% of the patients. As the lesion 
progresses, skin becomes adherent to the mass 
and it may rupture spontaneously, forming a sinus 
and an open wound.3 
 
The diagnosis of scrofula definitively is 
made by histology and culture of lymph node 
material. Other supportive tests that may be useful 
to raise suspicion include a positive PPD skin test 
and chest radiography indicating pleural 
thickening and apical fibrosis suggestive of 
previous TB.4 Fine needle aspirate (FNA) in 
seronegative HIV patients using conventional 
cytology, microscopy and culture has lead to 
inconsistent results,5 but one study report a 
sensitivity of 77 percent and specificity of 93%.6  
It is generally accepted that FNA is more valuable 
in HIV-infected patients.7  With new polymerase 
chain reaction (PCR) techniques some studies 
have found FNA to be almost equally sensitive to 
a lymph node biopsy.8 Ziehl-Neelsen staining of 
FNAs was positive in 87 percent patients with a 
final diagnosis of TB according to one study.9 
Excisional node biopsy can be performed if FNA 
and PCR are negative.  A finding of caseating 
granulomas on histopathology is highly 
suggestive of TB.10 Finally TB can also be elusive 
to culture taking up to 4-6 weeks but sensitivity 
testing can perform on the isolated organisms.11 
In the patient described here, cultures for TB are 
still pending to confirm the diagnosis as 
mentioned earlier. 
 
The mainstay of treatment for Scrofula has 
shifted from excisional biopsy to antitubercular 
agents. Treatment should be initiated before 
confirmative cultures return from the lab. The 
optimal duration has been found to be six months 
with multi-drug therapy including isoniazid, 
rifampin and pyrazinamide.12 Often patients 
return early after initiation of treatment because 
of a paradoxical increase in the lymph node size 
due to an immune response to the mycobacteria.13 
Response to therapy is excellent with relapse rates 
reported at 3.5%.14 
 
His preliminary microbiology results were 
negative for acid-fast bacilli and cultures up to 
one month did not show any organisms, however 
TB can be difficult to culture and the lab keeps 
cultures up to eight weeks to be certain. 
Resolution of the inflammatory mass after 
drainage would be expected, but a persistent 
draining sinus would be expected if TB is the 
underlying organism. Our suspicion of scrofula 
remains probable given the classical clinical 
presentation, negative cultures for typical aerobic 
and anaerobic bacterium, and negative chest X-
ray for active pulmonary disease.   
 
Due to international travel and the 
prevalence of TB worldwide scrofula is important 
to investigate especially due to the high mortality 
of disseminated TB and curative potential 
antitubercular medications. HIV positive patients 
and travellers to regions with high prevalence of 
TB should raise the suspicion of scrofula since 
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these groups are at higher risk.15 Therefore, as 
long as TB is around Scrofula should remain on 
the differential for unexplained neck masses. 
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Antibiotic resistance (ABR) is a growing health care problem. Literature suggests a lack of awareness may 
lead patients to pressure physicians towards inappropriate prescribing practices. Very little is known about 
what seniors know about ABR. This pilot study investigated knowledge of antibiotic use, expectations 
regarding the prescription of antibiotics and awareness of ABR in a community dwelling elderly 
population. Thirty-eight subjects (age ≥65) were interviewed at a London senior’s centre using a structured 
survey tool that explored knowledge and expectations about antibiotic use. Results reveal that 66% of 
respondents were familiar with the term ‘antibiotic resistance’ and that 90% felt it was an important health 
care issue.  Fifty-six percent of respondents obtained this information through media-related sources, and 
only 17% through their family physician (FP).  However, the majority of respondents (90%) felt that it was 
the role of the FP to inform the general public about the issue.  Regarding patient knowledge, 26% of 
respondents believed that antibiotics would help them recover from a common cold and 50% expected to 
receive antibiotics if they visited their FP for a cold. Of those patients who had recently been prescribed 
antibiotics, only 50% completed their prescribed course. These results illustrate the lack of knowledge held 
by elders regarding appropriate use of antibiotics and a significant discord between their expectations of 
their FP and the role FPs might play in educating patients about proper antibiotic use.  Study methods and 
the survey tool should be validated in larger future studies. 
 
Introduction 
 
ABR is an important healthcare issue that has 
significant implications for both the individual 
patient and for society as a whole.1-5 Several 
studies have shown that knowledge of ABR is 
lacking in some of the more educated segments of 
the North American population; however, 
literature regarding the knowledge of ABR among 
the elderly population, a group which uses a 
disproportionately large amount of antibiotics, is 
limited. Further, many physicians lack knowledge 
of proper prescribing practices.6-7 Improper 
antibiotic prescribing practices may lead to their 
unnecessary use and subsequently may contribute 
to the proliferation of resistant bacteria. Thus, 
correcting these practices could lead to a slowed 
increase in antibiotic resistance. 
 
The lack of patient knowledge regarding 
proper antibiotic usage has been shown in several 
studies to directly influence patient expectations 
from their physician encounters.8-9 Lack of 
education among patients often leads to pressure 
on physicians to prescribe inappropriately. 
Research has shown that physicians are especially 
likely to comply with such requests from elderly 
patients within their practice.10-13 One recent 
study found that 46% of general internists in a US 
hospital believed that patient expectations was 
one of the most important causes of antibiotic 
resistance.7 
 
Another significant cause of ABR is 
widespread misunderstanding regarding the 
importance of completing prescribed courses of 
antibiotics.10,14 This knowledge is particularly 
lacking among older adults, as is health care 
knowledge in general.15 Studies have shown that 
increased knowledge about medications leads to 
significant improvement in adherence and 
compliance with treatment regimens. This 
emphasizes the importance of assessing the 
knowledge of elderly patients regarding ABR and 
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educating this patient population about the 
importance of adhering to a prescribed antibiotic 
regime.9  
 
With the current lack of information on 
the knowledge of ABR and patterns of antibiotic 
use among the elderly, we designed a pilot study 
to better understand this important healthcare 
issue, specifically targeting a sample of 
community dwelling elders in London, Ontario. 
We sought to understand patient expectations of 
their physicians regarding the prescription of 
antibiotics, patient attitudes towards antibiotics, 
antibiotic usage patterns, and patient knowledge 
and understanding of the concept of ABR. 
 
Methods 
  
A standardized survey tool was administered 
through personal interviews by the student 
investigators at a local community centre over a 
period of three days in March-April 
2007.  Subjects were excluded if they were less 
than 65 years of age or residing in a long-term 
care or retirement home.  A community dwelling 
population was targeted under the premise that 
they would have more control over their 
medication usage patterns than those living in 
more institutional settings.   
 
Participants were not solicited. Rather, 
study participants voluntarily approached the 
student investigator’s table located in the lobby of 
the community centre. After obtaining consent, 
individual interviews were conducted by the 
student investigators.  No personal identifiers 
were collected and no remuneration was 
provided.  At the completion of the interview, a 
Letter of Information and a Health Canada 
information sheet regarding ABR were provided 
to each study participant to further their 
knowledge of this issue. 
  
Approval for this study was obtained from 
the Office of Research Ethics at The University of 
Western Ontario. 
 
Results 
  
Thirty-eight elders with a mean age of 77 years 
(range: 65-92 years) were interviewed.  Sixty-
eight percent were female, 100% had been 
employed at some time in their lives, and 97% 
reported currently having a FP (mean duration of 
professional relationship: 14.4 years).   
  
Regarding elders' expectations of their 
physicians, 24% indicated they would visit a 
physician for common cold symptoms such as 
cough, runny nose and a fever. Among those who 
would visit their FP for a cold, 56% expected an 
antibiotic prescription for their cold. Forty-seven 
percent of subjects believed that doctors usually 
prescribed antibiotics if patients felt they were 
needed. 
 
Regarding participant attitude toward 
antibiotic use, 87% of respondents felt they 
should not take antibiotics to prevent them from 
getting a more serious illness when they had a 
cold, whereas 26.3% believed that antibiotics 
would help them to "get better more quickly" 
from a cold.  Half of all elders 
interviewed believed that if they were sick 
enough to visit a physician, they would expect an 
antibiotic prescription (Table 1). Of those 
interviewed, 16% had used antibiotics within the 
last 4 weeks, with only 50% completing the 
course of antibiotics they had been prescribed. 
 
Sixty-six percent of respondents were 
familiar with the term 'antibiotic resistance'. After 
Table 1: Attitudes towards antibiotic use among community-dwelling elders   
Item % Agree % Disagree       % Unsure
When I get a cold, I should take antibiotics to prevent 
from getting a more serious illness. 
10.5% (4) 86.9% (33) 2.6% (1)
When I get a cold, antibiotics help me to get better 
more quickly. 
26.3% (10) 63.2% (24) 10.5% (4)
By the time I’m sick enough to visit GP from cold, I 
expect an antibiotic. 
50.0% (19) 47.4% (18) 2.6% (1)
Note: the number in the parentheses is the number of study respondents with this response. 
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being read a paragraph that described ABR, 92% 
felt this to be an important healthcare issue. When 
asked who should inform consumers about the 
issue of ABR, 90% of respondents felt it should 
be physicians, 55% stated pharmacists and 29% 
thought the media should educate the public.  Of 
those patients who had heard or read about ABR, 
most indicated that they received this information 
through public media (58%), 17% had received 
this information through physicians and 8% 
through their pharmacists.  Surprisingly, 84% 
indicated that their FP had never discussed the 
issue of ABR, and 97% had never received 
written information about antibiotic resistance 
from their FP (Table 2). 
 
Discussion 
 
ABR is a growing health care concern. Recent 
initiatives by Health Canada strive toward 
educating the public about appropriate antibiotic 
use and preventing unnecessary antibiotic use.  
This pilot study set out to investigate the 
awareness and knowledge surrounding these 
elders. The majority (92%) of the respondents 
considered ABR a very important healthcare 
issue.  However, there was large discrepancy 
between patient expectations and the information 
about antibiotic use provided by their healthcare 
professionals.   
 
Almost 90% of respondents felt that FPs 
should be responsible for informing patients, 
whereas only 17% of the respondents had actually 
heard about the issue from their FP. Surprisingly, 
it was media sources that had exposed most of the 
respondents to the issue. This is an important 
finding as the nature of the patient-physician 
relationship makes it one of the primary vehicles 
for reducing the number of unnecessary antibiotic 
prescriptions. Most patients have a strong trust in 
their physicians and educating elders regarding 
proper antibiotic use may promote better health 
outcomes for the patient and slow the increase of 
antibiotic resistance.  
 
Table 2: Knowledge of antibiotic resistance among community-dwelling elders 
Question % Agree % Disagree       % Unsure
Are you familiar with the term ‘Antibiotic 
Resistance’? 
65.8% (25) 34.2% (13) 0%
Do you think this is an important healthcare issue? 92.1% (35) 2.6% (1) 5.3% (2)
Have you ever heard or read about Antibiotic 
Resistance? 
63.2% (24) 36.8% (14) 0%
Has your Family Physician (FP) ever talked to you 
about Antibiotic Resistance? 
15.8% (6) 84.2% (32) 0%
Has your FP ever given your reading materials about 
Antibiotic Resistance? 
2.6% (1) 97.4% (37) 0%
Does your pharmacist talk to you about your 
prescription medications? 
84.2% (32) 15.8% (6) 0%
Note: the number in the parentheses is the number of study respondents with this response. 
 
Question Response
Who should tell people about antibiotic resistance? Doctor:               
Pharmacist: 
Media: 
Other:
89.5% (34)
55.3% (21) 
29.0% (11) 
5.3% (2)    
Among those who had heard or read about antibiotic resistance (n=24): 
Where did you get this information? 
Media:
Doctor: 
Family/Friend: 
Pharmacist: 
Other: 
Nurse:                 
58.4% (14)
16.7% (4) 
16.7% (4) 
8.3% (2)            
8.3% (2) 
4.2% (1)
Note: the number in the parentheses is the number of study respondents with this response; percentages do not 
total 100% as participants could select more than one option. 
(a) 
(b) 
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Although a majority of subjects stated that 
they were familiar with the term ‘antibiotic 
resistance’, our data indicate that this awareness 
did not necessarily equate to evidence-based 
antibiotic use. Twenty-four percent of 
respondents went to their doctor for cold 
symptoms and half of these patients expected a 
prescription for antibiotics.  While 87% of 
respondents did not believe that antibiotics could 
prevent a cold, 37% believed that they could get 
better faster using antibiotics.  These results 
suggest that even though a large number of 
subjects were familiar with the term ‘antibiotic 
resistance’, this did not translate to an 
understanding regarding appropriate use of 
antibiotics or knowledge of appropriate antibiotic 
use. This is thought provoking considering that 
the majority of subjects heard about ABR from 
media sources. Whether education of patients by 
physicians would lead to improved knowledge 
and behaviors around the use of antibiotics needs 
further evaluation.  
 
While this small pilot study raised some 
interesting points, further research on the topic 
will be needed to support these initial 
observations.  As with all studies, there are 
several limitations. Both the small sample size 
and use of a population attending a community 
centre make it difficult to generalize these 
findings to all community dwelling elders. A 
population regularly attending a community 
centre may differ significantly from a more 
sedentary population with respect to knowledge, 
attitudes, self-advocacy and health behaviors. 
Further, although the study questionnaire has face 
validity, further evaluation of the tool is needed.  
 
This study suggests that lack of patient 
knowledge regarding contributors to the 
development of ABR, as well as patient 
expectations of physicians and the prescribing 
practices of physicians could all be targeted in an 
attempt to reduce the incidence of ABR. Further 
research is required to better understand this issue 
and to evaluate the efficacy of potential strategies 
in reducing the development of ABR. 
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